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Abstract
To advance the causes of reducing medi cal errors and improving the quality of
patient care , healthcare is currently going through a period of vast reforms. CPOE
(Computerized Physician Order Entry) is one such reform. An important example
of CPOE is drug prescription, both of individual drugs and complex regimens , e.q.,
chemotherapy. By reducing medication errors , CPOE can both increase the quality of
patient care and decrease cost. Several types of problems may arise during the design
and implementation of CPOE systems. The most obvious of these problems are due
to insufficient attention being paid to the nature of existing manual clinical workftows.
Much more damaging are subtl e problems related to insufficient attention being paid
to the nature of the clinical workplace - in particular, the frequent lack of resources ,
e.g., system administrators and programmers, for ongoing system maintenance and
evolution after the system is deployed.
In this thesis, we will describe the development of an on-line chemotherapy pre-
scription system in which many aspects of system maintenance and evolution can be
performed by the system's users. The user-guided operational model underlying this
system overcomes many of the problems arising from limited system maintenance
and evolution resources in the target workplace. This thesis will also include several
discussions of various lessons learned during the development of this system that are
applicable to the development of medical informatics systems in general.
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Chapter 1
Introduction
1.1 M ot ivat ion
Almost all activities involved in th e process of impr oving a pati ent' s health are initi-
ate d via a writ ten order by a physician . Th is order is usually a prescrip tion, which
includ es ins tru cti ons for administe ring medicati on, or different test s for diagnosti c
purpos es. This initi al st ep or entry point for th e process of pati ent care is cruc ial, as
the ent ire care process is depend ent on it . In par ticular , a min or mist ake in prescrib-
ing, e.g., mistakes in dosage or frequency of medicat ion, can cause severe problems,
or in t he worst case this could result in the death of the patient. Hence, physicians
are requir ed to be very careful while writing such prescriptions.
In 1999, a repor t by the Insti tu te of Medicine, "To Err Is Human" [36], cited much
evidence to indi cate that in the United States alone, prevent able medication errors are
involved in 44,000 to 98,000 death s per annum (a grea te r death toll th an deaths due
to such fear ed thr eats as breast cancer, motor-vehicle wrecks, and AIDS combined)
and cost $17 to $29 billion per year. Thi s report and ot hers have renewed efforts
to apply information technology to clinical workflow in order to decrease medication
errors. Studi es have proved th at th e introducti on of a compute r in clinical workflow
can significant ly redu ce medication errors [61, 43]. Th e successful intr odu ction of a
comp uter syste m, e.g., CPOE (Com pute rized Physician Ord er Ent ry), can cause not
only a decrease in medication errors, but also enhance work thro ugh many aspects,
e.g., reduced cost, sta ndardizat ion of care and imp roved efficiency of care delivery [37,
59] . CPOE systems are remarkably helpful in redu cing prescription relat ed errors,
where prescription writin g involves complex calculat ions of dosage. Thi s moti vat es
t he developm ent of prescrip tion syste ms that can be helpful in makin g the prescription
process more accurate and impr oving the quali ty of patient care.
Such compute rizat ion is desirabl e; however , there are known probl ems th at occur
durin g th e developm ent of th ese syste ms, such as inattention to th e clinical workflow.
Th ese probl ems can be severe enough that th e resulting syst ems are often rejected by
physicians. If the promises of computer izat ion given above are to be realized , these
problems must be dea lt wit h dur ing syste m development.
1.2 Objectives
Given the prescription problem describ ed in motivation , as well as known problems
wit h impl ementin g compute rized solut ions to medical inform atics in genera l, this
thesis has two ma in objectives:
1. To deve lop a rest ricte d CPOE syste m for the chemot herapy prescrip tion process.
2. To present a number of lessons learned during the development of such a system
that are also relevant to medical informatics in general.
In the process of developing the required system, we have discovered what we think is
a gap in current software engineering theory and practice. This gap is related to the
assumptions that are made in software engineering practices and the actual operation
of the system both in terms of maintenance and evolution after deployment. Given
this gap, we also have a third objective of this thesis , to describe this gap and propose
a solution.
The reader should note that though software engineering techniques are used
extensively in the design and implementation of this system (and the description of
this design and implementation) , this thesis is not intended as a software engineering
thesis . Rather, it is intended as a contribution to medical informatics, as both a
demonstration of how a particular kind of system can be deve loped and the general
lessons that should be learned from this development process.
1.3 Contributions
The major contributions to this thesis are as follows:
• A detailed workflow analysis of the chemotherapy prescription process: This
workflow analysis was gathered by repeated weekly conversation with Dr. Far-
rell, under the Spiral software process development model (see Section 2.3.2.4).
These conversations allowed us to gather workflow not only because Dr. Farrell
was a chemotherapy prescriber himself, but also because he was the developer of
many of several previous chemotherapy prescription systems (see Section 3.3);
hence, these conversations access the experience of not only Dr. Farrell, but
all users with which Dr. Farrell himself interacted in developing his previous
systems. Similarly the workflow was also validated through these conversations
with Dr. Farrell (and hence also indirectly validated with the other system
users that Dr. Farrell talked to while developing his previous systems).
• A set of software development guidelines for medical informatics: These guide-
lines are encoded as various lessons learned during this project and are listed
at the end of Chapters 4, 5, and 6. We are aware that many of these lessons
are common sense in the software engineering community; however, it is still of
interest to list such guidelines here because these have particular importance in
medical informatics.
• Addressing problems of post-development system operation in medical infonnat-
ics: This involved developing what we believe to be an original classification of
post-development system operational models (see Section 2.3.3), and explain-
ing why certain medical informatics systems such as ~hemotherapy prescription
operate under a model that is not currently addressed in an adequate fashion
by software development practice. We also propose a solution to this problem
in the form of a democratic model of system operation (see Section 4.2.1).
1.4 Organization of Thesis
In Chapters 2 and 3, we describe the general problems with med ical informatics
software and look in detail at the prescription process, particularly as it relates to
chemotherapy.
• In Chapter 2, we will describe different types of medica l software/tools (Sec-
tion 2.1), prob lems that ar ise while developing them, and possible solut ions to
those prob lems (Section 2.2). We will see how software techniques are helpful
in developing med ical software (Section 2.3). We will discuss how the operation
of software after its development is important to consider while developing any
software. We will discuss in detail the different softwa re operational mode ls
defined in terms of software evolution and maintenance (Sectio n 2.3.3). We will
discuss which software process mode l and system operational model is appro-
pr iate for the development of medical systems (Section 2.3.5).
• In Chapter 3, we will discuss in detail both CPOE (Sectio n 3.1) and chemother-
apy prescription (Section 3.2) as a restricted form of CPOE system. We will also
examine different prob lems for the development of such a system that are intro-
duced due to the limited resources availab le for the maintenance and evolution
of a medical system during its operation. Finally, we will look at the prev i-
ous work that has been done to implement chemotherapy prescription systems
(Section 3.3) .
In Chapters 4, 5, and 6, we will look at the design, deve lopment, and implementat ion
of a chemotherapy prescription system. Note that at the end of each of these chapters ,
as thi s thesis is on medical inform atics, we will give in-depth discussions of the specific
lessons we draw for deve loping medical informat ics softwar e in genera l.
• In cha pter 4, we will discuss the design of a chemotherapy prescr ipt ion syste m.
We will describe the objectives of the system (Sect ion 4.1), and it's two key fea-
tures (Sect ion 4.2) , relate d to user interface design and a newly proposed model
of syste m operation, which we call the democratic model of syste m operat ion.
We identify syste m objects and classes (Sect ion 4.3) , and brea k the design of
the syste m into single-user (Sectio n 4.4) and multi-user (Sect ion 4.5) feat ures .
Finally, we will describe the database schema for the syste m (Sect ion 4.6).
• In Cha pter 5, we will look at different tec hnology choices, i. e., developm ent
framework , IDE, datab ase and webserver , that were made for the deve lopment
of our chemot herapy prescr ipt ion syste m. We will see how the choice of tech-
nologies for development of software is affected in the case of medica l software .
• In Cha pter 6, we will discuss the different system implement ati on models de-
scribing different ways to get software accepted in a target workpl ace. vVe will
discuss the different factors that affect the acceptanc~ of medica l software/tools
by health care.
Finally, in Chapter 7, we will provide conclus ions and a list of di rect ions for fut ure
researc h.
Chapter 2
Background
In this cha pte r , we will review different background topics for this thesis. Th ese
includ e genera l descrip tions of the ty pes of medical software (Sect ion 2.1), different
probl ems involved in the developm ent of medical software and their solut ions (Sect ion
2.2), and a description of software engineering tec hniques (Sect ion 2.3). Th e latt er
includes not only sta ndard tec hniques such as the software process model (Sect ion
2.3.1), bu t also includ es the software operat ional model (Sect ion 2.3.3), which is of
parti cular concern to the syste m developed in this thesis.
2.1 Medical Software
Modern health care organizat ions are designed and st ruct ure d to enhance the effi-
ciency of health care. Th e int rodu ction of inform ation technology into health care can
great ly enhance the process of quality pat ient care. Along with the basic effects of
int rodu cing compute rs to any workflow, i.e ., cost redu cti on and increased time effi-
ciency, compute rized workflow can reduce many flaws attached to manu al health care
workflow, which are explained later in this secti on with reference to different types of
medical syste ms .
However , heal th care organizat ions have given lit tle attentio n to th e intr odu ction
of compute rs to clinical workflow [14, 45]. If we explore the causes of such inatt ention
to th e clinical workflow fur th er , we will discover many imp ortan t and int erestin g facts
about health car e organiz ations. Th e clinical environment is different from any oth er
work environment, becaus e of th e uniqu eness and complexity which arise from th e
typ es of services , complexity of services , and motives behind the services it provides.
Thes e factors are further elaborate d later in this section.
Th ere are many typ es of medical systems, which are designed for use by different
user communit ies. Th ese communit ies includ e single doctor s, sma ll groups of doct ors ,
and large groups of doct ors. To exam ine past efforts for the det ails of successes and
failur es in an at te mpt to implement different ty pes of elect ronic medical syst ems, we
have divided syst ems int o three levels dependin g on syste m function alit y and type of
user community. Wh en we discuss each ty pe of system , we will describ e what that
syste m does, th e pot ential adva ntages it has, and wheth er or not it has been a success
in th e past in the USA and Canad a.
2 .1.1 Data Storage Systems
Th ese syste ms includ e Electronic Health Records (EHR) and Electronic Medical
Records (EMR) . Accordin g to th e HIMSS Electronic Health Record Committee, EHR
is defined as a secure, real t ime, point- of-care, pati ent- centri c information resource for
clinicians [30]. An EMR is concept ua lly different from an EHR , as an EMR is the ac-
tua l compute rized clinical record in different hospita ls and physician's offices, whereas
an EHR is designed to share data among different EMRs [27]. EHRs are reliant on
EMRs being in place and EMRs can never reach their full pote nt ial with out EHRs.
In both kinds of syste ms, pati ent dat a from different sources is store d in databases to
make it available to clinici ans. Thi s data can be scann ed images of pap er document s,
diagnostic images, or ot her type of medical data related to patients. EHRs and EMRs
are designed for many uses, from ind ividual clinics which have single-user EtvIRs to
hospit al level EMRs , which may have dozens or hundr eds of users . Hence, EMR s and
EHRs cover a broad spect rum of user communit ies.
A report by HIMSS on EMRs and EHRs establishes their ability to imp rove patient
care in th e following ways [30]:
1. Help ing to reduce medical errors.
2. Makin g access to pati ent dat a fast er.
3. Providin g remote access to data.
4. Allowing th e sharin g of data among different clinicians.
Despite the potential of EMRs and EHRs to ma ke cont ributions to the improvement
of health care quality, significant ini ti atives and st ra tegies to impl ement t hem in the
past have caused only a relati vely small num ber of sites in Nort h America to use
them. In 1991, the Inst itu te of Medicine (10M) [50] proposed to have comprehensive
impl ementation of EHR in the US over a period of 10 years. However , afte r 12 yea rs,
no more than 17-25 percent of the medical user comm unity employs EHR [32]. Like
the US, Cana da is also far behind in int rod ucing compute rs in the health care. In
Canada, major steps to introduce nation-wide EHR were taken through a multi -
million dollar investm ent by Infoway, fund ed by th e federal government. Infoway [15]
is a not for profit organiz ation which aims to pu t an int eroperable EHR int o place
across 50 percent of Canad a (by popul ation ) by th e end of the year 2009. However,
a report by Infoway states th at about 91 percent of physicians are still using pap er
records and /or prescribin g using pap er [14].
2.1.2 Analytical and Decision Support Systems
Ana lytical and decision support tools are design ed to help doctors in making critical
decisions on pati ent health. Analytical tools are used to access large transactional
datas ets by various dat a mining techniqu es. Th e results ext ract ed using thes e tools
can th en be visualiz ed using different knowledge repr esent ation methods. Th ese tools
can be used broadly to find th e useful patterns in health dat a which can help in
improving patient care, e.g., analyt ical tools to find adverse dru g events. Analytic al
tools may also be used for visual data analysis or image processing [53]. A clinical
decision support syst em is any system that helps in makin g diagnostic decisions for
pati ent car e [67]. Both analyt ical and decision support syst ems are typically focused
syst ems , aimed at single users or sma ll groups of users .
Work on clinical decision support systems originated in the 1970s, when systems
such as the de Dombals Leeds abdominal pain syst em [23] and the MYCIN syst em
[80] for selecting antibiotics, were developed. In 1999, Perr eau lt and Metzg er outlined
th e key benefits of clinical decision support syst ems [56]:
1. Supporting clinical diagnosis and tr eatm ent plan processes.
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2. Promoting the use of best practices in patient care .
3. Helping with cost reduction by reducing medication errors, and helping to avoid
duplicate and unnecessary tests .
Unfortunately, decis ion support systems are underused in a manner simi lar to that
seen with data storage systems. For examp le, a report by the Joint Clinica l Decision
Support Workgro up concluded that clinical decision systems are st ill used only by
minor ity of physician in their practice [77].
2.1.3 Computerized Physician Order Entry Systems (CPOE)
Order entry systems, such as Computerized Physician Order Ent ry (CPOE) are one
level above EHR /EMR. Such systems are designed on top of phys ician workflow and
are used to assist physic ians in accomp lishing patient-relate d tas ks such as ordering
tests and prescribing medications. The purpose of such syste ms is mainly to prevent
medication errors that are related primarily to prescription writ ing. Such systems
may have additional features such as decision support , patient safety features such as
rea l-time patient identification, and billing . CPOE is pr imari ly designed for use by
single doctors, though a CPOE system may serve a group of doctors.
Successful order entry systems are guaranteed to improve hea lthcare in the fol-
lowing ways [9, 20, 38, 60]:
1. Reducing th e prescription errors that are inherent in writ ing prescriptions which
involve complex calculations, such as chemotherapy prescriptions.
2. Giving direct access to patient data and history.
11
3. Removing int erpr et ation of illegible hand-wri t ten orders from th e workload for
nurs es and pharmacists .
4. Providing quicker turnover tim e for medicati ons.
5. Making data more readily available for oth er uses such as research .
Though the concept of order ent ry systems is very old , and resear ch has proven its
effect iveness in improving clinical processes [9, 20, 38, 60], it remains underused in
hea lthcare. Indeed, in the US and Canada, th e use of CPOE is even lower than the
use of EHR /EMR describ ed earlier in the section . In th e US, out of 17-25 perc ent
of users of EHR , only about 9.6 percent use some kind of elect ronic ordering syst em ,
which may includ e elect ronic prescribing or elect ronic lab test ord ering [21]. Similarly,
in Canada, less than 5 percent of physi cians use elect ronic ordering systems [14]. As
ord er ent ry syst ems , and specifically Computerized Physi cian Order Entry syst ems ,
are th e subject of thi s th esis, th ey are discuss ed in more det ail in Section 3.1.
2.2 Developing Medical Systems: Problems and
Solutions
In the previous sections , we have looked into different medica l systems shown to be
helpful in improving th e process of patient car e and not ed that despite th e benefits
of such systems, their usage is low. If such syst ems are guaranteed to improv e th e
qualit y of healthcar e, but are not widely used, th en there must be factor s involved to
prevent th eir adoption. In thi s sect ion, we will explore the probl ems und erlying such
minim al use of medical syste ms and that mus t , therefore , be taken into consid erati on
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when designing medical systems. We have divided these problems into two categories:
system development problems (Section 2.2.1) , which affect the development of a med-
ical system, and system operation problems (Section 2.2.2) , which arise during the
use of a system after deve lopment.
2.2.1 System Development
In this section we will identify and briefly explain the different prob lems that arise
while chang ing from a man ual med ical system to an electronic medica l system. We
will also discuss how these problems have affected the introduction of medica l systems
in health care and how (if at all) they have been add ressed.
2.2.1.1 Importing Legacy Knowledge
In order to make legacy data readily available to physicians in new electronic systems
older patient data must be added to electronic patient records . Th is add it ion of
data can be expe nsive and difficult , as it may include scan ning all pape r records
into an electronic form. This transfer of data from paper to a scanned digital format
needs carefu l attention to ensure that all necessary details are tra nsfer red successfully.
Unfortunately, research has shown that many physicians find patient data hard to
understand in a scanned digital form, which causes them to revert back to manu al
systems [39J. Importing patient data is also difficult as it involves the assimilation
of medica l knowledge from different sources into the new system. T hese systems are
often further complicated due to the use of specific medical terminology, as systems
which use non-standard medical terms are likely to be rejected by the users .
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Scanning old patient records and adding them to new syste ms should be considered
only as an interm ediate ste p towards developin g a fully elect ronic medical record [39].
Thi s st ep not only eliminates the probl em of slow processing and rigid stru ctur e
in sca nned docum ents , bu t also makes th e elect ronic data more readil y available
for sharin g, administ ra tive, and resear ch purp oses. However , in order to prevent th e
possibilities of errors involved in th e manual addit ion of dat a to a database, necessary
validity checks are requir ed to ensure th e correct ness of th e dat a. Moreover , to deal
with th e problem of usage of medical terminology, it is important to work in close
collaborat ion with th e act ual users of th e syst em , i.e., physicians , who will be obliged
to work with th e medical terminol ogies employed by th e system.
2.2.1.2 Interoperability
Interop erabili ty is an imp ortant issue if we are to merge dat a from different sources
to make it available for sharing among the users of those sources . Most sta nd-alone
medical syst ems are developed and targeted for a parti cular depar tm ent or hospit al
and lack any shar ed convent ions of dat a with ot her sources. This restri cts large
amounts of medical dat a to only one medical syst em at a tim e and rend ers that dat a
useless to other syst ems th at could benefit by sharin g it [24, 42].
In ord er to mak e dat a available for sharing from different sources it is necessary to
standardiz e medical dat a. Th ere are many standards , such as Health Level 7 (HL7)
[31], th at can be introduced as guidelines to enable th e exchange and int erop erability
of electronic health records. HL7 intr odu ces a set of "ru les of conversa t ion" th at
enab le different syste ms to communicate patient-centri c data. In Canad a, Infoway,
which has invested millions of dollars provided by the Canadi an government, has
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esta blished a set of guiding prin ciples for inform at ion sta ndards. Infoway is also
leveraging HL7 messaging, which is standard thro ughout Nort h America [24].
2.2.1.3 Legal Issues
Th ere are many legal issues involved in use of EHR and electro nic prescribin g systems,
which make the developm ent process more complex. Priv acy laws make it difficul t
to share dat a among the users of elect ronic health data, i.e., th e person al dat a of
a pati ent or th e histor y of his medical record is not allowed to be open for genera l
access like resear ch work or administ ra tive use with out the consent of th e patient .
For exa mple, und er the Food and Dru g Regulations in Canada a pharm acy is allowed
to fill only those prescrip tions that are ordered by physician in a writ ten or verb al
form. Food and Dru g regulati on states: "C.01.041 (1.1) Subject to C.01.043 and
C.01.046, no person shall sell a substance containing a Schedule F drug unless (a)
the sale is ma de pursuant to a verbal or written prescription received by the seller;"
[41]. Moreover , there are ma ny hurdl es related to the creat ion of and maintenance of
medical record s which make the developm ent and main tenance process more complex.
To overcome th e privacy problem , we need to deal with the priva cy of patient s
and medical professionals very carefully. Wi thin the health care inform ation syste m,
there is an emerging need to ensure th e securit y and int egrit y of healthcare data while
maint ainin g pati ent privacy. A relati onal dat abase is a good solut ion to probl ems re-
lated to privacy and secur ity issues, where data can be sto red in t ables and limi ted
access can be gra nte d to each person according to his/ her privileges. Moreover, to
enhance privacy, field protection can be applied to ta bles to restri ct access to indi-
vidual colum ns. To make data availab le for research, we can use various techniques,
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such as data anonymisatio n, to preserve privacy [75].
In addit ion to such technical solut ions, we can also deal with legal issues by deve l-
oping legislation that ta kes into account the specific concerns of health informatio n.
For exa mple, a possible solut ion to the legal issues involved in electro nic prescribing
has been proposed by the Nat ional Association of Ph ar macy Regulatory Auth ori ties
(NAP RA) , which has developed genera l recomm end at ions for thc safe and effective
tr ansfer of prescriptions between prescrib ers and pharmacist s. Th ey identify five prin -
ciples that should be met for safe tr ansfer of elect ronic prescriptions, which are also
supported by th e Health Canadas Th erap eut ic P rodu cts P rogramm e (T P P) [51]:
1. Th e process must main tain patient confident iality.
2. Th e process must be ab le to verify the aut hent icity of the prescrip tion , i.e., that
the prescriber is initi atin g the prescrip tion.
3. Th e syste m must be capab le of validat ing the accuracy of the prescrip tion, and
the process must include a mecha nism to preve nt forgeries.
4. Pati ent choice must be protected; that is the patient must det ermin e the prac-
t it ioner to receive the prescription aut hority.
Legal issues within many ot her areas of health inform ati cs could be resolved by sim-
ilarl y st ruc tured legislation. In any case, such issues are not cur rent ly handl ed by
software engineering meth ods and probably will not be handl ed in futur e; hence,
they will not be addressed in this thesis.
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2.2.1.4 Social and Organizational Issues
Modern health car e organizat ions are confronte d wit h new clinical e-healt h technolo-
gies as never before. Early evidence suggests th at the ado pt ion of new medical soft-
ware/tools depends in large part on th eir accepta nce by both hospit al bur eau cracies
and by doctors. Thi s acceptance must ta ke into account var ious social and organiza-
t ional issues related to the behavior of doctors and burea ucrats within the hospital
environment. Th ese issues and behaviors are discussed exte nsively in [49]. Th e fol-
lowing condenses some of the main points in th at discussion , and divid es th ese issues
into two categories: bur eaucrati c and physi cian .
Hospit al bur eaucracies show the following behavior towards th e adoption of new
software/too l:
1. The a p proval p ro cess: It is very difficul t for a medical tool to be approved
by hospi tal bur eaucrats. Thi s is prim arily due to caut ion about adop tion of
new tools because a minor erro r in t hose tools could harm pa tients health and
even cause deaths. Moreover , th e bur eaucracy also has to consid er th e complex
secur ity and privacy issues associat ed with th e adopt ion of new software.
2. Limit ed IT r esou r ces: Many developm ent probl ems aris e because of limited
hospi tal IT resour ces. For example, th e developm ent of some dat abas e-enabl ed
tools may requir e dat abase administ rat ion, bu t a hospit al 's IT department may
not have any dat abase admini str ation personnel to spare.
3. Preference for existing tools: As hospit al bur eaucracies t rust only exist ing
too ls, they ask for new tools/so ftware based on, and thus similar to, th ose too ls.
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Thi s similarity falls in two catego ries:
• Look and feel: Hospital bur eaucracies insist that new too ls use the same
interface as exist ing too ls or, in the case of a paper-based syste m, they
requir e new tools to have t he same inpu t and display form at as th at syste m.
• Underlying technologies: Bur eaucrats are more comforta ble using new
tools which are based on tec hnologies th at th ey are already famili ar with .
Doctors show t he following behavior towar ds the adopt ion of new too ls/software :
1. Need for familiar look: Even if they agree to use new tools, doctor s need
these tool s to have same int erface and look as too ls wit h which th ey are already
famili ar , i.e., th e int erface of th e old syste m.
2. Difficulty in extracting workflow descriptions: Due to th e busy sched-
ules of doct ors, it is somet imes very hard to get useful descriptions of clinical
workflow from th em. Thi s may resul t in the development of a syst em with in-
sufficient inform ation about the ta rget workpl ace and users , leadin g to a failur e
of adopt ion.
3. Cannot be compelled to change: Doct ors have a responsibili ty to pati ent
care which they always main tain as priorit y. Hence, no one can compel th em
to adopt a new technology which they do not feel serves th at priori ty.
Thi s last behavior is par ti cularly imp ort ant , because it highlights a cruc ial difference
between th e relati onship of doctors and the administ ra t ion in hospit al and the re-
lati onship between employees and the administ rat ion in compa nies. In a company,
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the workers are employees of the company and can be compelled by the administra-
tion to make any change related to work. However, the relationship between doctors
and hospital is not so much that of employees but rather that of private contractor;
therefore it is much more difficult to compell doctors to make any changes requested
by the administration . This difference in relationship has implications for software
adoption. In an ordinary company workers can be told by the administration or IT
department to adopt a new technology, while the successful development of medical
tools /software requires that doctors and administrators both see the benefits and
hence agree to adopting a new technology.
The problems that occur during the development and acceptance of medical sys-
tems due to social and organizational issues that are specific to the medical field have
been given very little attention in the past [40, 59]. This inattention was a cause
for the failure of many medical informatics systems, where either physicians refused
to accept new systems or stopped using medical systems to protest against them,
e.q., the Cedars-Sinai hospital uninstalled a multimillion dollar system as physicians
stopped using it [40]. There is not really an effective solution available in software
literature to overcome these problems, but it is recommended that designers involve
physicians in the development process as much as possible. This is related to the issue
of physician champions in medical software development, which will be discussed in
more detail in later sections of this thesis.
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2.2.2 System Operation
We have discussed many development problems and their solutions in the previous
section. Let us now consider the prob lems that are associated with system operation.
System operation is concerned with the issues related to short, mid, and long term
system evolut ion and maintenance, i.e. , what a system does after it is developed.
Here, issues related to mai ntenance are how system changes that arise from the day
to day usage of the syste m, e.g., adding a new users to system, are handl ed. Syste m
evolut ion is related to the need for change in the basic design of a syste m that arises
afte r using that syste m for a long period of time . For exa mple, in the case of a
chemot herapy prescr iptio n system, if the basic method of prescri bing chemot herapy
drugs is cha nged, it will cause a need for a corresponding change in the design of the
system. T hese issues are especially important for systems which are deve loped for a
longer period, making it more likely for these issues to corne forth.
Tho ugh system operation issues occasionally come up in software deve lopment,
they are not satisfactorily addressed in software engineering literatur e at present.
T his is particularly unfortunate for us, as many med ical informatics systems are long
lived and face these problems. T his will be discussed in more detail in Sectio n 2.3.3.
2.3 Software Development
From Sectio n 2.1 and Sectio n 2.2, we see that medical software prese nts some in-
teresting developmental prob lems . Here we will ana lyze these prob lems in terms of
two components of the software development process, the software process mode l and
the system operational model, and we will see how appropriate software engineering
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techniques can help us to solve many of the problems arising during the development
of medical informatics systems. In this section, we will briefly describe what each
model is (Section 2.3.1 and 2.3.3), and the types of each model (Sections 2.3.2 and
2.3.4). The discussion of types of system operational models (Section 2.3.4) is partic-
ularly detailed, as this is not, to our knowledge , adequately addressed in the software
literature. Finally, in Section 2.3.5, we discuss which software process and system
operational models are most relevant to medical informatics.
2.3.1 What is a Software Process Model?
A software process model may be defined as a simplified description of a software
process which is presented from a particular perspective [69]. In other words, we
can say that a process model is a plan of action for a large and complex software
development , which includes a clear statement of what is required and the different
tools , steps and series of steps, required to successfully implement a software product
[10, pp. 21-22].
In the early days of computers, software development was still evolving . Because
projects were small, the programmers' own defined ways-of development were suf-
ficient to produce successful software. The most common way to develop software
was to write code and then test it, and came to be called the build and fix model.
With the passage of time, software projects became more complicated and difficult to
develop with traditional programming techniques due to lack of knowledge about the
software implementation. To overcome this problem new development models, also
called software development paradigms, were introduced to cover the whole software
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developm ent life cycle. Th ese models includ e a compre hensive guidance toward s the
developm ent of software .
A mod el, also called th e life cycle of a project developm ent , consists of different
phases, which can range from thr ee (for a simple mod el, including Design , Develop-
ment , and Maint enance) to more th an twent y phases. However , most of th e models
includ e the phases of Requir ement , Design, Impl ementation , Testin g, Deployment ,
and Maintenance. Different pro cess models includ e different iterati ons and orders
of th ese phases, which make them suita ble for par ti cular circumsta nces. Hence, th e
selection of an appropriate model depends on th e natur e of th e proj ect and its con-
st ra ints.
2.3.2 Types of Software Process Models
Tod ay, we have many software process models , all of which are act ually variations of
four traditional software mod els.
2.3.2.1 Waterfall Model
Th e wat erfall mod el was introduced by Royce in 1970 and is also called th e linear
sequential model [63]. In thi s model the following phases are complete d in order.
1. Requir ement Specificati on
2. Design
3. Impl ementati on
4. Testin g
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5. Deployment
6. Maintenance
In the Waterfall model one should only move to the next phase on the completion
of previous phase. There is no jumping back and forth, and there is no overlap
between the phases. In spite of the fact that the system being developed is always well
documented from the very beginning of the process, one of the main disadvantages
of the Waterfall model is that not every part of the product is available until late in
the development process. Thus, if mistakes or deficiencies exist in the documentation
or earlier phases, they may not be discovered until the deployment of the software.
Hence, correction must often be done in the maintenance phase. Because of its
sequential nature, the Waterfall model is not applicable when the requirements are
not clear and well understood at the start of the project. Moreover, in the Waterfall
model the actual participation of the end user is negligible, and only the final version
of the product can be delivered to users, which makes it unavailable for comments by
the client in earlier stages .
2.3.2.2 Incremental Model
The Incremental model was introduced in 1975 by Basili [8]. The Incremental model
is a series of waterfall cycles, where the requirements are known at the beginning
and are divided into groups, and the initial group of requirements is fulfilled at the
end of a series of several waterfall builds. Hence, this model can get evaluation from
the client by showing a working part of software after each cycle, which can allow
both alterations during development and the addition of new requirements during
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the implementation of the system. In the Incremental model a usable product is
available after the first release , and each iteration results in additional functionalities
for the product . However , in this model , users are required to learn the new system
developed in each cycle. Thus , the Incremental model is beneficial for projects where
feedback is necessary from customers at early stages of project development.
2.3.2.3 Prototyping Model
This model, also called the Evolutionary model , was introduced by Floyd [26] and
simply refines the prototype system in each iteration. Working software is built in
the first iteration and then refined in later subsequent iterations. The specification,
development, and testing phases are carried out concurrently. Rapid feedback is made
possible by adding customer evaluation in each cycle. The final system will accurately
fulfill the user needs; however the project is often started without full knowledge of
requirements and thus needs greater coordination with the user.
2.3.2.4 Spiral Model
The Spiral model was defined by Boehm in 1988 [12]' and!s recommended for high-
risk projects where the requirements must be refined and the user's needs must be
met. The Spiral development model involves incremental builds which identify areas
of risk and decide how to overcome and eliminate chances of risk via the validation
and verification of the project in each iteration or build of the product. As such,
it is obvious that the Spiral model combines features of the Waterfall , Incremental ,
and Prototyping models , and hence provides a great deal of user involvement and
risk management. If we compare the Spiral model in more detail with other models,
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its distin cti ve featur e is that it deals wit h the risks and uncertain ti es involved in
softwa re deve lopment . Th e Spiral model exp licit ly recognizes the following risks and
uncer tain ti es [10]:
1. During long developments, the users are neglected in the process of gat hering
their requir ements.
2. Th e users requirements are misunderstood .
3. Th e users change requirements.
4. Th e target hardware configuration changes .
Th e disadvantage of using the Spira l model is its complexity and greate r cost. How-
ever, given the high risk associated wit h medical software , this is the preferred model
for medical syste m development (see Sect ion 2.3.5 for more discussion).
2.3.3 What is a System Operational Model?
A syste m operat ional model is a descr ipt ion of the short to mid term maintenance
and evolut ion require ments for a given system. Here, system mainte nance is support
that is availab le for the operation of a syste m, which could eit her be support from
the deve loper of the syste m or sup port by the system adm inist rato r, who is availab le
onsite or cont racted to perform different act ivit ies necessary for such syste m to keep
them up and running . Syste m evolut ion is how syste m requir ements evolve in the
short to long ter m duri ng a syste m 's operation. Bot h mai ntenance and evolut ion are
changes to the syste m that require resources ; hence, system operat ional model is the
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descrip tion th at includ es not only the natur e of maintenance and evolut ion bu t also
tak e into account th e resourc es that are availabl e to make th ose changes.
How are syste m maintenance and syste m evolut ion ty pically handl ed in software
engineering? Th e usual approach is to assume that there will always be sufficient
resour ces for unlimi ted evolut ion and main tenance, i.e., one or more syste m adminis-
tr ators and one or more programm ers will always be there to brin g about the changes
requir ed to handl e evolut ion and maintenance. Under th e assumpt ion of unlimited
change resourc es, th ere is no need to explicit ly describ e sys tem evolution and maint e-
nan ce. Inst ead , to deal with any futur e change in syste ms, prop er software engineer ing
practi ces are adopted when the ini ti al syste m is developed , e.g., st ruc tured program-
ming is used and all necessary docum ent ation is done, such that it is easy to make any
cha nges which are necessary in the futur e. Unfort una te ly, as we will see in th e next
section , th e assumption of unlimited change resources is not tru e for cert ain syst em
operational environments.
2.3.4 Types of System Operational Model
Th ough th ere is no explicit mention of syste m operat ional models in th e software
engineering lit erature, there appea r to be thr ee ty pes . Unl ike syste m pro cess models,
which depend more on the compl exit y of th e syste m, syst em operational models de-
pend on the user community and to a lesser degree on th e applica t ion being developed .
Th ese three ty pes are as follows:
1. Large Organizational Model: Thi s includ es organizat ions that have ef-
fecti vely unlimited resources available for sys tem maint enance and evolut ion.
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Th ese organizat ions can use their resour ces for syste m administ rat ion, and can
handl e any cha nges which they may want in their syste m du e to long te rm
syste m evolut ion.
2. Personal Model: Thi s includ es standa lone syste ms developed for personal use.
Users using such syste ms possess very limi ted resources for the maintenance and
evolut ion of their syste ms .
3. Small Organizational Model: Thi s includ es small organi zati ons or focused
groups in large organizat ions, such as a cancer clinic in a large health care or-
ganizat ion. Th ese organizat ions have limit ed resources available, and cannot
usually afford system maint enance and evolut ion.
Thi s is to our knowledge an original classificati on of syste m operation mod els. We
believe that thi s classification is useful not only for showing how exist ing syst ems
operate, bu t also for showing ty pes of syste ms not adequa te ly addressed in cur rent
software developm ent pr actice. Thi s ordering of models may look somewhat stra nge,
but this is the historical order in which these models emerged. To fully und erst and
t he differences between these three models, it is useful to 100k at thi s histori cal order
in more detail.
Thi s historical orde r can be nicely visualized in te rms of a 3 x 2 tabl e (see Table
2.1), whose dim ensions are ty pes of available support and size of user communit ies.
Th e ty pes of support are:
1. No Support: A workpl ace where no syste m administ rat or is available and no
or very lit tl e support is available from t he developer of the syste m.
27
2. Partial Support: A workplace where support is available but is available
either part-time onsite or full-tim e off-site , e.g., support available via phon e
from the developer of the syste m.
3. Full Support: A workpl ace where support is available both , full-tim e onsite ,
i.e., sys tem admini str ator s and programm ers hired by organizat ion, and/or full-
tim e off-site.
Th e typ es of user communities are:
1. Single-user systems: Single-user systems were first introduced in th e 1970s.
Th ese syste ms are developed for a sta ndalone compute r and are less complex
and less expensive th en mul ti-u ser syste ms.
2. Multi-user Systems: Mul ti-u ser syste ms were first introduced in the 1950s,
when it was common for big organizations to use such syst ems . Multi-user
syst ems are more complex and expensive th an single-user syst ems . Due to th eir
complexity and different functi onaliti es such syste ms requir e full supp ort and
dedicat ed technical support on site.
Not e th at two possibl e combinations of support and user communit ies are very rare:
Multi-user systems with no supp ort , and single-user syste ms with full support. Hence,
they are not addr essed below.
Let us now look at the historical order in which th e models emerged. Wh en
computers were first intr odu ced th ey carne only in a multi-user environment. Ini ti al
compute r syste ms in 1950s were ta rgete d to hundr eds or thousands of users, and
those mul ti-u ser syste ms were, by definiti on , complex systems . Organizations that
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were using such mult i-user syste ms had their own IT divisions , or had the resources
to contract different companies for the full system support. T hese systems were
developed under the Large Organi zational Mode l. In the late 1970s and early 1980s
sta nd alone syste ms were int rodu ced for the use of single users. Th ese syste ms were
simple, but had no support from the developers. Users using these syste ms were
expecte d to be smart enough to be able to fix any problems that might arise while
using them. Th erefore, th ese syste ms were effectively und er the Personal Model.
At this point we have pur e versions of th e first two models. However , th e era
of the mid 1980's saw the introducti on of par t ial support , which did not affect big
businesses, but did change the Personal Model by moving it from th e upp er left
corne r down the column. In this model, users who pay several thousand dollars for
a syste m receive help from designated sta ff belonging to the vendor compan ies who
created these syste ms. Because of the large number of users ent itled to such services,
provid ing support to them was not an issue for big vender companies, du e to the
economic facto rs involved. Hence, single-user systems were the first ty pe of syste ms
for which partial sup port was provided. As more and more people got into the market
one of the ways for syste m deve lopers to ret ain market share became the provision
of user support . Thi s now meant that by th e addit ion of par tial support , single-user
syste ms could become more complex, and in turn could be adapte d to th e needs of
small organizat ions. Thi s led to the emergence of the third operat ional model, the
Small Organizati onal Model.
Now that we have seen how these three models emerge d, let us examine how each
mode l dea ls wit h the issues of software maintenance and software evolution:
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1. Large Organizational Model: In th e case of the Large Organizational Model ,
as such organizations have effect ively unlimited resources, they can afford to
allocate these resources as necessary for both system maintenance and evolution.
2. Personal Model: In the case of the Personal Model , for maintenance, either
the person or the developer company is responsible for system maintenance and
evolution. For future system evolution under this model , software companies are
always trying to establish the needs of their users. As the number of personal-
system users is large, big software companies can invest a lot of money to make a
good general package for them. Hence , personal computer evolution is handled
very well. In the case of system maintenance, as companies sell these systems to
many users, they have the resources to maintain them and to provide support,
such as 24/7 help lines or technical support available over the web to correct
problems. As systems under the personal model are relatively simple compared
to multi-user systems, partial support is sufficient for their maintenance and
evolution.
3. Small Organizational Model: In the case of the St;lall Organizational Model ,
organizations lack the resources to handle the maintenance and evolution. More-
over , these organizations do not have the numbers to encourage the emergenc e
of vendor companies that will provide them with even partial support.
As we can see from the above , there is a gap in how to deal with a system operating
under the Small Organizational Model. One way to deal with maintenance for these
organizations is that we can minimize the need for full time system administrator
support by building systems in such a way that the system users can handle adminis-
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tration themselves. To handle evolution, in case of organizations whose activities are
small and very circumscribed, with sufficient design during the development of the
system; we can also put the evolution of such systems in the hands of their users.
To handle system operation in the Small Organizational Model , we have intro-
duced a democratic model of system operation (see Section 4.2.1) . Though this mode l
is described in detai l in Section 4.2.1, the following points shou ld be noted here ; first,
we have built this mode l so that system changes that are required based on day to
day activ it ies are in the user 's hands. Second, although the syste m administ rato r
cannot be fully removed from the loop, minor day to day changes can be made by
the users using th is democratic approach, so that even partial support is sufficient.
2.3.5 Which System Process and Operational Models are
Appropriate for Medical Informatics?
By looking at the comp lexity of medical systems and taking into consideration the risk
involved in the process of developing a medical tool, the Spiral model (see Section
2.3.2.4) seems to be the most appropriate one . As this mode l needs strong user
involvement in the process of development, there is a need to find computer literate
physicians who can act as phys ician champions and can help throughout the process
of deve loping a successfu l med ical tool.
The system operational model depends on the type of med ical system being de-
veloped. For EMRs/EHRs, and general drug orders CrOE will fall under the large
organizational model. Decision support systems, if they are done frequently enough,
will fall under the personal model. Infrequently used decision support systems and
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ta rgete d CP OE syste ms will fall und er the Sma ll Organizational Model. Hence med-
ical informat ics too ls fall into all three catego ries of system operational model. In
Cha pter 3, we will see that chemot hera py prescr ipt ion systems fall und er the Small
Organizat ional Model and we will show in detai l how limited resources can cause
problems for the operation of such systems.
Tabl e 2.1: Types of System Operationa l Models
Single-User Multi-User
Environment Environment
Personal V
XNo Support
( 1970's )
Personal V Orga nizat ional
Partial Support [Small] 7
( 1980's+ ) ( 1990's+ )
Organi zati onal V
Full Support X [Large]
.( 1950's+ )
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Chapter 3
Chemotherapy Prescription
In this chapter we will look at a particular type of order entry system associated
with chemotherapy prescription. Such a system is an example of a CPOE system
(see Section 2.1). CPOE systems can be of a generalized nature, covering all types of
medical prescription writing, or can be targeted systems, where a system is designed
to computerize a specific type of medical treatment such as chemotherapy. Targeted
CPOE systems inherit all the problems of the generalized CPOE, but also introduce
some new problems due to their targeted nature. Hence , in this chapter we will
discuss CPOE in general (Section 3.1), and we will look af an example of a targeted
CPOE, a chemotherapy prescription (Section 3.2). Finally, we will review previous
efforts to develop chemotherapy prescription systems and we will sketch the form of
an idealized system that builds on this work (Section 3.3).
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3.1 CPOE
In Section 2.2, we looked at the prob lems associated with medical software in genera l.
In this section, we will look at these problems in the cont ext of th e particular system
of int erest to us in this thes is, namely CPOE. In this section, we more closely exam-
ine the definition of CPOE (Section 3.1.1), and we review th e benefits and prob lems
associat ed with CPOE imp lementation (Section 3.1.2), as well as the prob lems (Sec-
tion 3.1.3) . Finally, we will summarize the factors associated with successful CPOE
imp lementation (Section 3.1.4) .
3.1.1 What is CPOE?
CPOE (Computerized Physician Order Entry) is the gener ic name for a comp uter
app lication which was introduced as an effort to eliminate the chance of errors , such
as errors in ordering medication by a physician (see Section 3.1.2) . To eliminate
the chance of errors, instead of writ ing orders on a prescription pad, the prescriber
enters an order directly into the computer. The funct iona lit ies of CPOE systems
vary in different CPOE tools. Kaushal and Bates describe the bas ic funct ionalities
of CPOE too ls as follows: ". .Basic CPOE ensur'es standardized, legible, compl ete
orders by only accepting typed orders in a standard and complete [ormat ,.. Basic
clinical decision support may include suggestions or default values for drug doses,
routes , and frequencies ... " [35]. Advanced CPOE systems may include , but are not
limited to , decision support , drug dose recommendation, drug interact ion notification,
and billing [13].
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3.1.2 Benefits of CPOE
Studies have shown that CPOE systems are effective in reducing the medication errors
that frequently occur in the paper based system currently in use by the majority of
medical service providers [9, 20, 38, 60]. Note that even a basic CPOE system can
be very helpful in reducing calculation errors in prescriptions which involve complex
calculations (such as protocols for cancer chemotherapy or HIV therapy). These and
other benefits are described in more detail below .
3.1.2.1 Reduction of Medical Errors
Every year, thousands of patients world-wide die as a result of medication errors
[36]. Mistakes such as errors in dosage, improper routes of administration, and wrong
dosage schedules, among others, are typically responsible for such events. Such mis-
takes have at least two causes: The first cause is Doctors' poor handwriting, which
sometimes leaves pharmacists squinting to read drug names or dosages, and causes
them to provide improper medication or dosages by misunderstanding the prescrip-
tion. The second cause of medication errors arises when prescription writing involves
complex calculations. Given the actions of some drugs, especially the cell toxic drugs
involved in chemotherapy, any mistake in calculation of dosage has potential to cause
patient 's injury or even death. This problem is compounded when prescriptions in-
volve multiple drugs; for example, in a chemotherapy prescription, a selection of drugs
is given and the dosage of each drug involves calculations (see Section 3.2.1 for de-
tails) . Even if neither of the above problems is present , the prescription is written
perfectly, and everything is calculated correctly, adverse drug events (in which several
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drugs combine to have unexpected side effects) can cause another category of errors
where wrong combinations of drugs can cause harm to the patient.' .
CPOE systems are regarded as the solution to medication errors which arise from
prescription writing. CPOE solves the problems of poor handwriting, as all prescrip-
tions are computer generated and all calculations are done by computer, eliminating
the chance of calculation errors. Moreover, CPOE can check the possibility of any
known adve rse drug events automatically. The resu lts of CPOE can be impressive;
pu blished st udies have shown that CP OE can preve nt 81 perce nt of erro rs related to
presc ript ion writ ing [9, 20, 38, 60].
3 .1.2.2 Time and Co st
Most studies on CPOE benefits are related to CPOE's ability to reduce medication
errors, as this is the primary purpose of CPOE systems. However, CPOE systems
also have the ability to reduce overall hospital costs . Evans et al [25], have shown that
CPOE systems help to reduce the cost of medication and the length of hosp ital stays
by reducing the number of orders for antibiotics when anti -infective-management
programs were used. Moreover , the abi lity of CPOE to reduce adverse drug events
also causes a decrease in the costs associated wit h such events, which are, according
to a report by the Insti tu te of Medici ne, abo ut 2 billion dollars a year [36].
IThere is anot her type of error related to deficiency of medication knowledge, which may occur
because of less experienced physicians entering into the field, or when physicians occas ionally find
themselves outside their normal area of expertise [IIJ. Though this could potentially be mitigated
by computerization, i.e., an appropriately designed expert system , this is beyond the scope of this
thesis and will not be considered further herein.
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3.1.2.3 Research Purposes
Electro nic data is always attractive for researc h purposes. CP OE data is sto red
electronically in itemized form in databases, i. e., not in scanned docum ent form ;
hence, it provid es elect ronic dat a which is more readil y available for research, which in
turn can impro ve the qualit y of health care. For example, in the case of chemot hera py
t reat ment, where different combinat ions of drugs are used to t reat cancer, medical
data can help researchers to find the best combinat ions of dru gs for the t reat ment of
par ti cular typ es of cancer.
3.1.2.4 Administrative Purposes
A compute rized medical syste m like CPOE can be useful for administ rat ive purp oses,
such as evalua t ion of clinical sta ff performa nce . For instance, useful inform ation can
be retri eved about how often a parti cular dru g is prescribed by th e physician and how
much a parti cular dru g costs per year . In this way, administ rators can maximize th e
effectiveness of their resource allocat ion.
3.1.3 Problem s wit h CPOE
CPOE has been und er discussion for over 35 yea rs, which has lead to an und erstandin g
of many problems with CPOE syste ms. In 1970, Collen [19] introduced the concept of
CPOE by listing the general objec t ives of Medical Inform ation Manag ement Syst ems ,
and stated that, "Physicians should enter medical orders directly into the computer".
Following this, there were various efforts to implement CP OE systems. Sit tig and
St ead [68], in 1993, summa rized the previous work done related to CPOE. Accordin g
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to their pap er most of the efforts made in the 1970s and 1980s met wit h failure .
Technology const ra ints at that t ime , costs, and lack of computer literacy wit hin the
medical profession were amo ng the major causes of these systems' failures.
Oddl y, recent impl ementati ons of CPOE at different sites do not show significant
improvements, desp ite advance ments in tec hnology and sufficient compute r literacy
in the medical profession. As a result , many of these efforts have failed . For example,
Cedars-Sin ai Hospi tal in Los Angeles impl emented a mul timilli on-doll ar CPOE in lat e
2002 and thr ee months afte r implement ati on , th e tool was unin stall ed as physicians
complained about the poor design of the syste m [40]. If technology has improv ed , the
cost of tec hnology has decreased, software design and impl ementation meth odologies
have impr oved , and comp uter literacy in the medical profession has improv ed , then
other reasons must be responsible for the failur e of these syste ms .
Th e main reason for these failures seems to be a lack of respect by syste m deve l-
opers for the clinical workflow, in pa rt icular, where insufficient attent ions has been
paid to the details of going from manu al to computer ized workflow [40, 59]. Thi s was
acknowledged by Michael L. Langberg, M.D. , Chief Medica l Officer at Cedars-Sinai
Medical Cent er , who stated that, "One of the m ost im portant lesson s learned to date
is that the complexity of hum an change management m ay be easily und erestimat ed"
[40]. We will discuss this in much greate r det ail when we look at the specifics of
chemot herapy prescrip tion in Sect ion 3.3. In the next sect ion, we will discuss the
factors that make for a successful CPOE system.
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3.1.4 Factors in Successful CPOE Im plementations
As seen in previous subsect ion, many CPOE systems have failed because physicians
sto pped using them, and one of the main causes seems to be inat tenti on to clinical
workflow by syste m developers. Ph ysicians need a syste m that is guara nteed to
help them provide qualit y care to their pati ent s and, obviously, th ey cannot make
compromises in pati ent care . If a too l is designed in keepin g with established physician
and health care workflows (which are already known to work well) , th en th ere are fewer
chances for th at tool to fail. Thu s, to make CPOE accepta ble for physicians to adopt,
it must have at least th e following properties [6, 78]:
• It should be accura te and reliable so as to positiv ely affcct patient care .
• Whil e impl ementin g CPOE syste ms, legacy syste ms cur rent ly in use by th e
health care providers should be taken into considerat ion.
• Ph ysicians should be given full authority to make any decisions ab out pa-
tient health. Imp osing something against a physician 's final decision should
be avoided .
• It should be fast enough th at it improv es th e speed of workflow or at least it
shou ld not be slower th an th e exist ing system .
• It shou ld be easy to use and should requir e minim al tr aining for effective use.
A striking feature of medical work is th at it is fast paced . Phys icians have littl e
t ime to spare to learn new technologi es. Hence, th e new CPOE syst em should
be simple enough th at it ta kes lit tle tim e for physicians to learn it .
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• Interface issues should be ta ken into consideration while designing such syste ms
and the interface should be consiste nt thro ughout the system.
• It should have sta nda rdizat ion with respect to medical procedur es and te rmi-
nology and a workflow that can be effectively impl emented in health care.
• Durin g syst em impl ement ation , physicians should receive any help th ey need to
change th eir workflow st ra teg ies and habit s.
• Aft er th e syste m has been impl ement ed, online help should be availabl e.
Th ese are th e minim al requir ements for a successful CrOE impl ement ation . It is
st rongly recomm ended that, to fulfill and to und erstand the above cha rac te rist ics,
physicians should be an act ive par t of the impl ementation. Thu s th ere is a need to
search for compute r literate physicians, referred to as "physician champions" through-
out the literatur e [59, 65], if the process of impl ementation is to be successful.
Wh en compared to "ordi nary" software, the developm ent of medical software/ tools
is much more complex and risky, as if it is done incorrectly, people can die and it
will have excessive costs (see Section 3.1.2). Careful considera t ion should be given to
make sure th at th e appropriate software process model is selected to deal with this
complexity. Moreover , we also need to choose th e appropriate system operation al
mod el. This is necessary because CrOE, as not ed earlier, comes in several sizes. Th e
genera l CrOE falls und er Large Organi zation al Model. However , as we will see in
next sect ion, chemot herapy prescrip tion seems to fall und er the Small Organi zational
Model. It means that chemot hera py prescrip tion has fewer available resources, and
its impli cations will be discussed and dealt wit h in the remaind er of this thesis.
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3.2 Chemotherapy Prescription
In this sect ion , we will now exa mine a specific typ e of CP OE in det ail , i.e., chemother-
apy prescrip tion. We will st ruct ure this syste m in parallel with that for CP OE, by
first giving a description of chemothera py (Sect ion 3.2.1 ). Recall th at one of th e
main probl ems with CPOE is not payin g attent ion to the workflow of healthcare sys-
tem. Th erefore, we give an overview of chemot herapy prescription workflow (Sect ion
3.2.2 ), and we will see how this ma nua l workflow can be improved by repl acin g it
with compute rized workflow (Sect ion 3.2.3) . We will look at th e benefits of the com-
put eriz ed workflow (Sect ion 3.2.4 ), and considerat ions concern ing th e developm ent of
compute rized workflow (Sect ion 3.2.5) .
3.2.1 What is Ch emotherapy?
Chemotherapy refers to th e use of dru gs to tr eat an illness (chemotherapy = chemic al-
th erap y) [31 . Wh ere cancer is concerne d , chemothera py is used to eit her destro y cancer
cells completely or , when this is not possibl e , to cont rol th e growth of th ese cells [21 .
Most cance r chemot hera pe ut ic dru gs have been chosen because th ey act as poisons
that att ack dividing cells. Th e ty pica l side effects of cell-toxic dru gs result from th eir
effects on ot her rapidly dividing cells such as hair follicles and bon e marrow , which
pr odu ces new red and whit e blood cells . Short- term effects of chemothera py include
hair loss, bone marrow suppress ion, anemia, and susceptibility to infection.
Th ere is a large numb er of different dru gs that are used to treat cancer. Each
typ e of cancer is only sensit ive to par ti cular drugs , and there arc many differen t
ty pes of dru gs. In most cases, a combinat ion of dru gs, also called a drug r egimen,
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is given in order to maximize the efficiency of th e tre atment. This combination
of drugs is also called combinational ch emother ap y . Each chemotherapy drug
has an associated dosage, route of delivery, frequency of application, and associated
additional instructions as well as a collection of emetogenic levels which vary from 0
to 5 based on the dosage of that drug. The dosages of the drugs depend on both the
type of cancer, and on patient characteristics such as height and weight (see Section
4.4.1.3 for detai ls). Antiemetic drugs are also part of each drug regime n, to min imize
the side effects of chemot herapy drugs (see [49] and references). Ant iemet ic drugs are
selected based on the emetogenicity level of the chemotherapy drugs which are part of
regimen (see Section 4.4.2.2 for algorithm to select antiemetic drugs) . Each ant iemetic
drug has an associated dosage, route of delivery, and frequency of application.
3.2.2 Manual Chemotherapy Workflow
T he man ual chemot herapy workflow is shown in Figure 3.1. Th e physician makes
decis ions based on the patient's history and med ical conditions. T hese decisions
could involve writing a new prescription for a new patient or altering or continuing
an old prescription. The prescription is then sent to the pharmacy.
T his manual workflow has the following categories of prob lems:
1. Immediate problems: The process of chemot herapy involves calcu lations
based on the patient's height and weight. A minor mistake in these calcu lations,
mistakes in the schedule of dosages, or improper methods of administration can
have severe effects on the patient's health, Moreover , physicians' notoriously
poor handwriting often leaves pharmacists squ int ing to decipher a dosage e.g .,
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Figure 3.1: Workflow Diagram: Manual Chemotherapy Prescription Process
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10 milligrams versus 10 micrograms. Th ese mistakes can even happ en wit h the
name of prescrib ed dru gs (see Secti on 3.1.2).
2. Secondary problems: Patient data in files are not read ily available for sec-
onda ry uses such as research work or generat ing reports. It is almost imp ossible
for a physician to get a report based on large groups of pati ent s, as it would
cost too much tim e and money to compile a report based on pati ent dat a stored
in pap er files. Similarly, pati ent dat a can only be used for research purp oses if
it is st ripped of names and ot her identifyin g inform ation , which is difficult to
do in the manu al chemotherapy workflow.
j oti ce th at many of these problems can be resolved by the compute rized workflow
describ ed in th e next subsect ion.
3.2.3 Computerized Chemotherapy Workflow
From Section 3.1 on CPOE and Secti on 3.2.1 on the chemot hera py prescription pro-
cess, we can see th at the chemot hera py prescription process is an ideal case for the
impl ement ation of CPOE. Such impl ement ation can great l reduce th e inh erent prob-
lems at ta ched to th e manu al chemotherapy prescription workflow mentioned in pre-
vious subse ction. One possible compute rized workflow is shown in Figur e 3.2. Noti ce
th at this computerized workflow is designed to have as few differences from th e man-
ual workflow as possible. However , one big difference in this computerized workflow
is that patient and regimen data is now sto red in electro nic form in databases.
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3.2.4 Benefits of Computerized Workflow
In additional to the benefits attached to the implementation of a CPOE syste m that
are describ ed in Section 3.1.2, the impl ementation of a targeted chemot hera py CPOE
syste m offers solut ions to the probl ems related to manu al workflow:
1. Fixes to immediate problems: Wi th many chemothera py regimens com-
prised of cell-toxic chemicals that must be indi vidu alized to pati ent s' height ,
weight and diagnosis, deliverin g chemot herapy effectively and safely requi res
specialized knowledge and st rict attent ion to det ail. Compute rized ent ry of
such prescriptions can help to overcome potenti al probl ems of errors in dosages
due to complex calculations. A computerized chemotherapy syst em can also
help in fixing th e problems that arise from the physicians ' poor hand writin g.
2. Fixes to secondary problems: A dat ab ase can also help doctors in gen-
era t ing repor ts and looking beyond an individual pati ent to see how similar
pati ent s with similar medical histories and cult ura l backgrounds have been di-
agnosed and trea ted for similar problems. Similarly, a dat abas e can be made
available for research work provided privacy is guaran teed to th e involved par-
ties. Thi s can be made possible by st ripp ing off names and oth er personally
identifi abl e inform ation or by anonymizing datasets by ent ry modifi cation [75].
Along with the fixes to prim ary and seconda ry problems mention ed above, we have an
addit iona l benefit. Researchers are cont inuously t rying new combinat ions to improv e
the qu ality of chemot hera py. Th ese new combinat ions can be stored in th e dat abase
to make th em available to physicians in the prescribin g process. Th e compute rized
syste m can now not only inform th e physician about upd at es in chemotherapy dru gs,
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bu t will also let the physician add new regimens, which they have found effective
against a par ti cular cancer, to th e dat ab ase for ot hers to use. Th ese new regimens
can be added into a pri vat e or publi c pool based on the consent of th e physician who
is adding th em (see Section 4.4.2.2 for more det ails).
3.2.5 Consideration Concerning Computerized Workflow
Along with the long list of CP OE impl ementation considera t ions given in Section
3.1.4, the big thing which we need to consider for t he developm ent of chemotherapy
prescriptions is th e system opera t ional model. CPOE is a mid-sized medical infor-
mati cs applica t ion where we are dealing with anywhere between 3-10 doctor s, who
are int eractin g with 1- 5 pharm acist s. Chemot hera py and chemotherapy equipment
are ty pically assoc iate d with cancer clinic. Regardl ess of wheth er or not this clinic
is affiliate d with a hospit al , th e cancer clinic will probably not be able to get full
support with respect to syste m administ rato rs and programm ers to deal with syst em
evolut ion and maintenance. In Secti on 4.2.1 we will see how thi s probl em can be
solved by the introduction of a democrati c syste m operat ion model.
3.3 Previous Work
In the previous sect ions of thi s cha pter, we noted that there are two issues that
need to be addressed while developin g a medical syste m: respect for exist ing clinical
workflow and the syste m operationa l model. One aspect of workflow is decidin g how
to handl e erro rs. If one of the big benefits of CPOE is the reduction of errors then
one can handl e errors in one of two ways: One can make it as difficul t as possible
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Figure 3.2: Workflow Diagram: Computerized Chemotherapy Prescription Process
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to make errors, or one can make it as easy as possible to do the right things . In
this section, we will discuss different attempts that have been made in th e past to
change the manual chemotherapy workflow shown in Section 3.2.2 into the idealized
chemotherapy workflow detailed in Section 3.2.3. Past work that has been done can
be divided into two categories based on the type of error-handling strategy followed
while designing systems.
Systems using the first strategy make it hard for users to make errors . This is
typically done by implementing rigorous error checking and by making sure that there
is no deviation from the design workflow. In the case of medical systems, which are by
definition complex systems, development using this approach is likely to compound
the complexity of the system by making it difficult for the users to do what they need
to do. For example, if the diagnostic workflow is implemented in a rigid fashion, such
that a doctor cannot view a patient history unless that doctor is already treating that
patient, i. e. , the doctor has already ordered the lab tests for that patient, a doctor
in emergency board will not be able to write prescription for a patient, that has
just come under their care. Such problems have resulted in the failure of physician
to fully adopt such systems. To our knowledge, the rna 'or available chemotherapy
prescription systems have all used this strategy. They are general CPOE systems,
such as Opis 2000 [54] and Meditech [44]' that have been customized to work for
chemotherapy. Sample screenshots of Meditech are shown in Figures 3.3. Note that
while these systems are built under the philosophy of making things in such a way
that it make hard for people to create errors, they are incredibly difficult to use .
Moreover, as these systems use the Large Organizational model , any customization
for use by small organizations such as cancer clinics is very difficult to do.
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Figure 3.3: Screenshots: Medite ch - (a) Patient Profile (b) Finding Patient.
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Systems using the second strategy make it easier for users to do the right thing .
This is typically done by a more flexible implementation of the workflow and a less
rigorous approach for error checking, in which errors are flagged but allowed if the
doctor considers it necessary. For example, during patient data entry there may be
some normal range check on data; if a doctor enters data outside the range , this
potential error will be noted but allowed if physician finds it necessary. Note that
part of this certainly involves the reengineering of the user interface, but this type of
flexibility also has to be design ed in to the system from the start of development.
To our knowledge , there are no commercially available systems that follow this
strategy. However , Dr. Gerard Farrell , of MUN Health Sciences , over the last decade,
has built a series of three systems on this philosophy:
• Version 1 was developed by Dr . Farrell in 1995. It was a set of hem-oncology
chemotherapy prescription pages developed for the Newfoundland Cancer Treat-
ment and Research Foundation (NCTRF) using Microsoft Excel. A sample
prescription page is show in Figure 3.4. This version computerized the pa-
per prescription forms , and did automatic calculation of chemotherapy drugs
dosages , hence reducing the chances of calculation errors. However , this version
had many problems because each oncologist had his own copy of prescription
pages, i.e., Excel sheets; hence, these pages were essentially open source and
copies could be modified independently. Moreover, if someone altered the for-
mula behind a dosage cell by mistake, it could lead to severe dosage errors.
Minor changes in any drug regimen needed changes in all physical copies of
that regimen , which was difficult to coordinate and enforce. Similarly, th e addi-
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tion of a new regimen involved the distribution of new copies to all physicians.
Finally, prescription pages were technology dependent, and as the prescription
pages were designed using Microsoft Excel, users had to have Microsoft Excel
installed on their computers to view and use these pages .
• Version 2 was built by Dr. Farrell in 1997. It was a set of web-enabled pre-
scription pages using Java Script. Sample pages of a prescription are shown
in Figures 3.5 and 3.6. This system had hard coded web prescription pages,
which solved the problems of technology dependence and as the system was
implemented on web, there was only one copy of each regimen. Unfortunately,
storage of prescription and patient data was not possible in this version .
• Version 3 was a collaborative effort of Dr. Farrell with the MUN Computer
Science Medical Informatics Group; the result of this collaboration appeared
as a student project [49]. This version was developed using Java Server Pages
(JSP) [72], (a Java technology that dynamically generates HTML and XML),
and prescription pages were attached to a database for storage of precription
and patient data. A sample prescription input page ~s shown in Figure 3.7, and
the corresponding output page is shown in Figure 3.8.
Note that the third version overcame the problems associated with Versions 1 and
2, but it still lacked abilities of the idealized computerized workflow described in
Section 3.2.3. All three versions were judged to function well with respect to the
second workflow and error handling philosophy stated above. With respect to system
operational models, though all were adequate to the extent that resources required
for installation were minimal, there was no mechanism for modifying these systems.
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~ " " "'" ,m~" ,~HealthCare thl'l'ttof Patient
CO'f'o.. ' .... oIStJOOn ·.
Ho<p.& W>rd
I.lCP Uumbtr
Medicine Program Ch' rt Uumb-f r
Ph ysician 's Chemotherapeutic Medic atio ns
General Hospital Site
IHeiqht = ems IV....eicnt = kqsl
I BSA= 0 00 m2 I
ITotal Bili = IALP = ICr= I
Diagnosis- Drug Allergies-
Date-
Round off tote! dosages where appropriare
CHOP
"CYCLOPHOSPHAMIDE
750 mg/m2 = o mg in 100 mls Normal Saline IV
over 1 hour
DOXORUBICIN
50 mg/m2 = o mg (in a syringe) IV push
VINCRISTINE
1.4 mg/m2 = 0.0 mg (MAXIMUM 2 mg)
in 20 mls Normal Saline
'p'REDNISONE
(in a syringe ) IWpush
100 mg PO od for 5 days
Ant i-Emetics :
Dexamethasone 10 mg IV pre-chemo
Ondansetro n 8 mg PO pre-cherno & 8 hrs POst chemo
Maxeran 10 mg POIIV q4h pro
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Figur e 3.4: Farre ll Version 1 - Sampl e Pr escription Page
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Antineoplastic Drugs Prescription Form
-~et;=:
Facsimi<t:
737-6795
AC(60/600), Cycle #r-
Percent of Protocol Dose Intended by Physician: riOO%".:::.l
Drug Name Dose Dose(mg) Route Frequency(mg/m 2 )
IMaxeran (Metoclopromide) .::l rI03 I po .::J pre-chemo
IAnzemet (Dolasetron) .:J p:oo- pre-ehemo
Figure 3.5: Farr ell Version 2 - Sample Prescription
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Ipo .:J pre-cherno
Adriamycin (Doxorubicin)
Cyclophosphamide
(60)
(600)
--..:J 1--:3 pre-chemo
iv O;:i~30 Day 1 Only
iv over 1 hr Day 1 Only
Total hydration (in mls) should equal the dose of Cyclophosphamide (in mgs).
This prescription represents I % of the full dose as per the protocol
This prescription has been rounded off by the signing physician if this box is
checked: r
Signature : _
Figur e 3.6: Farr ell Version 2 - Sampl e Pr escription (Cont 'd)
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Th ere was no mechani sm for crea t ing a new regimen or alter ing an exist ing regimen
which requir ed a programm er to add new pages or mod ify existing ones to make any
change or introduce a new regimen ; ind eed, as the implemented version 2 syste m
aged, physicians were forced to modif y system pages by manu ally overwrit ing th e
fields on th e pap er out puts. Moreover , note that none of those versions was explicitly
mul ti-u ser or had even basic secur ity featur es such as password- authorized access to
the syst em.
In the next cha pte r, we will look at the design of a chemothera py prescription
syste m along th e lines of th e Farr ell syste ms which solves all probl ems with Versions
1 through 3 mentioned above. Moreover , to support tru e multi-user functi onality,
our new system has abilit ies above and beyond the idealized compute rized workflow
describ ed earlier.
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Figure 3.7: Farre ll Version 3 - Samp le Prescription Input Page
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~ Patient Name JohnHopkinsHtqJ!~J;~qre
Hosp.& Ward Hematology
MCPNumber 234-543-234
Medicine Program
Physic ian's Chemotherapeutic medic ations
ChartNumber 23
Ge nera l Hospita l Site
Height Weight t kgs
CaiculatedBSA = 2.01 m' BSAused=2.01nr
TotaiBili=4 ALP= 5 CR=2 5
Diagnosis-nil DrugAllergies-nil
Dale: Saturday,Augustll ,20076:29 :53PM
CHOP
Protocol Dose Calculated Dose Prescribed Dose
CYCLOPHOSPHAMIDE
750mg/m' 1S07mg 1500mg in 100 mls Normal Saline
IVover 1 hour
DOXORUBICIN
SOmglm' 100mg 100mg (in a syringe) IVpush
VINCRISTINE
1.4mglrn> 2mg 2mg (MAXIMUM 2 mg)
in 20 mlsNormal Saline
(in a syringe) IVpush
PREDNISONE 100 mg PO od for 5days
Drug Name Dose (mglm2) Dose (mg) Route Frequency
Maxeran(Metoc1opromide) 10 po pre-chemo
Anzemet(Dolasetron) 100 po pre-ch eme
Decadron(Dexamethasone) 8 po pre-chemo
Ativan(Lorazepam) 0.5 po pre-chemo
Physician's Signature
Figur e 3.8: Farr ell Version 3 - Sampl e Pr escrip tion Output Page
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Chapter 4
System Design
In this chapter and the succeeding two, we will design and implement a chemotherapy
system along the lines sketched at the end of Chapter 3. This system will be devel-
oped under the Spiral model, which we have discussed in Chapter 2 as the best for
developing medical informatics software (see Section 2.3.2.4). As we are building this
new system to operate under the Small Organizational Model (see Section 2.3.4) , we
need to design the system in such a way that it 's operation fits the limited resources
of the target workplace . In terms of user interface, we will give our system a similar
look to the previous systems pioneered by Dr. Farrell , and we will use the same error
handling philosophy used by these systems (see Section 3.3).
This chapter is organized as follows: We will first describe the objectives of our
system (Section 4.1) ; as part of this we will describe the two key features of this
system (Section 4.2), the democratic model of system operation, and our user interface
philosophy. This is followed by a brief description of the objects in this system
(Section 4.3). We will then describe the features associated with single-user functions
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and mul ti-user functions of the syste m (Sections 4.4 and 4.5). The description of each
function includ es a descrip ti on of workflow wit h a workflow diagram", a discussion of
design decisions made relate d to that funct ion, and one or more scree nshots associate d
wit h the impl ement ation of that funct ion in the chemotherapy presc ript ion syste m.
Thi s is followed by the detailed descrip tion of the database schema impl ementin g the
objects described in Sectio n 4.3 (Sect ion 4.6). Fin ally we will sum marize the lessons
learn ed while designing our chemot hera py prescr ipt ion syste m (Sect ion 4.7).
4.1 System Objectives
In this sect ion, we will give a genera l overview of syste m object ives and functi onaliti es;
the details of speci fic tas ks are included in specific subsect ions later in this chapter.
Th e syste m objectives can be broken down into single-user and mul ti-user capabilit ies.
Given th e descrip tion of idealized compute rized workflow in Section 3.2.3, we requir e
the following single-user capabilit ies:
• Th e syste m should allow physicians to add new patients and to search for ex-
istin g patients in the database. Moreover, the system should be able to keep
patient profiles in order to allow physic ians to look at the histories of pat ients.
1It may seems contradicto ry t hat we are using flowchart s (which assume a rigoro usly defined
workflow) to spec ify workflow when in Sect ion 4.7, we claim that requireme nts in medical informatics
software deve lopment are more often stated as flexible guidelines. Readers shou ld therefore interpret
the workflows flowcharts given in this t hesis as t he normat ive processes i.e., t he processes that occur
90 percent of the ti me, and exceptio na l sit uations (which occur in the remainin g 10% of t he time)
are then superimposed on these flowcharts.
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• The system should allow a physician to prescribe a regimen to any patient. Due
to ongoing research, regimens change frequently over time; hence, the system
should offer different functions to create new regimens and alter existing ones.
Moreover, the system should have a convenient regimen management system,
where regimens should be organized in to different lists, i. e., primary and sec-
ondary, based on frequency of their usage. This is to provide quick access to
regimens at the time of prescribing.
• The system should have a drug database and physicians should be able to add
drugs to the database.
Given the requirements for multi-user operations implicit in Sections 3.2.3 and 3.3,
we also need the following capabilities:
• The system should allow only authorized access to it.
• Physicians should be able to view the history of patients, which may include
prescriptions issued by other physicians.
• Regimen data should be divided into public and private lists, such that a physi-
cian can choose to make a regimen public at the time of creation, and any
physician can import a regimen from that public list to his/her private list at
any time (see Section 4.5.2.1).
• Prescription data derived from regimens must be public. Any physician looking
at the patient history must be able to look at the prescription history of the
patient, where he can cancel any past prescription but can make changes to
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only those prescriptions th at were prescrib ed by him /her (see Secti on 4.4.1.3
for detail s) .
Th ere are several oth er mul ti-u ser capabilit ies, i.e. , changing the name or emet o-
genicity pot enti al of chemotherapy dru gs and adding or deletin g users, which, while
suggest ed by the indi vidu al users, should act ually be decided by th e whole user com-
munity. One solution for this would be to provid e a mechanism for makin g, votin g
on, and resolving prop osals within the user community (see Secti on 4.2.1 for det ails).
4.2 Key Features
Given th e syste m describ ed in Secti on 4.1, two key design features are a demo crati c
model of syste m operation to deal with short to mid-t erm syst em evolut ion and
maint enance, and th e user interface. In thi s sect ion, we will discuss both of th ese key
features in more det ail.
4.2.1 Democratic Model of System Operation
In Chapt er 2, we discussed th e operation al probl ems, i.e .,"sys te m evolut ion and sys-
tem maint enance, at tac hed to small organi zation s. In Ch apt er 3, we realized th at
th e chemothera py prescription system we are going to develop falls und er th e Small
Organi zati onal Model. Thu s, we have to deal with short, mid , and long term syste m
evolut ion and main tenance und er th e assumpt ion th at th e target workpl ace does not
have enough resour ces to deal with such operat ional problems.
To handle syste m maint enance and evolut ion, we are going to put as many as-
pects of syste m maint enance and evolut ion as possible into th e hands of the users
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themselves. We have named this the Democratic Model of System Operation.
To handl e changes in both single-user and mul ti-user environments, we have buil t the
syste m to be flexibl e enough that individual users can make only those changes that
do not affect other users. Wh en a change affects more than one user, the democrati c
process is invoked ; this app lies for bot h evolution and maintenance. Under th e demo-
cratic model, in order to fulfill a requested change which affects mul ti ple users, we
have implemente d a vot ing mechani sm. To request a change in the syste m, users can
issue new pro posa ls and ot her users may vote on them . Th e details of this vot ing
mechanism can be found in Sect ion 4.5.
We have split the later design sect ions into single-user and multi -user. Under the
democrati c model, the aspects of maintenance and evolutio n are scat te red in both
single-user and multi-user functi ons. In single-user cases we have features to create
or alte r regimens and to import a regimen to a user 's privat e list . Meanwhile, most
of th e mul ti-u ser functions fall und er the democrati c model of sys tem administ rat ion.
Note that the democratic model is not a perfect solut ion for a syste ms operat-
ing und er the Small Organizat ional Model. Th e democratic model can successfully
handl e short to mid- term changes . However , long-term oha nges such as changes in
the algorit hm for the calculat ion of emetoge nicity potenti al (see Secti on 4.4.2.2) or
fund amental changes to the way in which chemot hera py is prescrib ed cannot be han-
dled by our prop osed democrati c model and will requir e the int ervention of comp uter
professionals. Th at being said, there is no suggeste d solut ion to such problems in the
softwa re engineeri ng literatur e, and at least our proposed model can handl e short to
mid te rm changes well.
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4.2 .2 User Interface Design
T he user inter face design of our chemotherapy prescription system has the following
cha racte rist ics:
• To make it easier for the users to adopt the new syste m, our chemot hera py
prescription sys tem mimi cs the format of the older pap er-b ased versions , such
th at th e prescription pages look exac t ly th e same as pages of th e old syst em and
different features of the system mimi c th e workflow of th e physici an . Thi s is in
accordance with physician and bur eaucrati c behavior toward s software tools as
describ ed in Section 2.2.1.4.
• To follow th e erro r handling approach describ ed in Section 3.3, i.e. , to make
it easier for users to do the right thing, our chemotherapy prescrip ti on syste m
has minim al interference in the workflow. For exa mple, the syste m does not
use popup windows to dist ract users when the syste m finds any potenti al error;
instead , to noti fy the user of these potenti al errors, different color schemes are
used, such th at the color of field is changed to red for the field with th e potenti al
error and a message is displayed on th e top of page.
Each of t he tasks and subtas ks describ ed lat er in this cha pte r are illustrat ed with
screenshots from th e implement ed user int erface. From th ese screenshots , it can be
seen th at th e impl ement ed user int erface has th e charac te ristics describ ed above.
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4.3 System Objects and Classes
Before we describe in detail the tasks and subtasks making up the system in Sec-
tions 4.4 and 4.5, let us first describe the obj ects in th e system. There are many
objects implicit in the system as sketched in Chapter 3. However these objects can
be divided into two groups : Entity objects, and Control objects. From an object-
oriented perspective, an Entity object represents an object in the real -world problem
domain while Control objects are responsible for workflow, imp lementation and task
sequencing, as well as user navigation through the system [76].
The system has the following Entity objects: Physician , Patient, Regimen,
Prescription, Chemodrug , Antiemetic, and Administrator. Note that Physician ob-
jects correspond to users of the system. The system has the following Control ob-
jects, which represent the individual components/tasks of the system: Login, Lo-
gout , PasswordRetri eval, AddUs er, Deletellser, AddPatient , PatientSearch, AddDrug ,
CreateRegimen, Alt erR egimen, ImportRegimen, RegimenManagement , PrescribeRegi-
men, CancelPrescT'iption, EditPrescription, ViewRegim enList, AddComments, View-
Comments, AddProposal, and VoteProposal. The implementation of the Entity ob-
jects in terms of database schema is described in Section 4.6. Though Control objects
are invoked to implement the tasks and subtasks described in Section 4.4 and 4.5, it
is not necessary to examine the details here and they will not be referred to in the
remainder of this thesis.
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4.4 Single User Design
Workflow associated with single-user is subdivided into smaller subtasks, These sub-
tasks are grouped into three categories based on activity duration: single-session
(Section 4.4.1), short-term (Section 4.4.2) , and mid-term (Section 4.4.3). This break-
down of tasks into sma ller subtasks is shown in Table 4.1.
Before we look into the actual description of each task , we would like to give an
overview of the level structure and class naming conventions used in Table 4.1. As
this system is designed relative to the MVC model (see Sect ion 5.2), it is split into
th e following three layers:
1. Presentation layer: The presentation layer includes all form beans'', which
also act as the form data validation layer. In Table 4.1, all classes that end with
Form are part of the presentation layer. Notice that a few tasks do not have
Form classes involved in them. This is because those part icular tasks do not
include any form data. Hence , for any task X, if it includes form data there is
a class XForm , which acts as a form bean and also validates the form data.
2. Business logi c layer : The business logic layer lie"sin between the presenta-
tion layer and the data layer and includes classes that are used to handle the
information exchange between a database and a user interface. In Tab le 4.1 all
classes that end with Act i on are part of the business layer. Notice that , for all
2 A Java Bean is a Java class that follows a specific set of interface specifications. It is a reusable
software component that can be manipulated in an app lication builder tool. A form bean is a type
of Java bean. A form bean stor es HTML form data from a submitted client request and the data
bean provides a simple representation of an entity bean [741.
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t asks in th e ta ble, there is a corresponding Action class attached to it , which
performs th e necessary functions to fulfill that task. Hence, for any Task X,
th ere is a class XAction to perform t hat tas k.
3. Data layer: Th e data layer or dat a object layer is responsible for th e creat ion
of dat a beans to be t ransferred to th e business layer. Hence, for every database
t able th ere is a corresponding data bean class with the same name. Notice
that for all dat a bean class X there is a corresponding XData class that is
responsible for connect ion to the datab ase, and for makin g all ty pes of queries
to th e dat ab ase tabl e encoding dat a of typ e X. Here, also noti ce th at a numb er
of th e ent ity obj ects th at we have seen in th e previous section also map to th e
dat abase tabl es. For each ent ity obj ect there is one or more corresponding tabl e
in th e dat ab ase; see Section 4.6 for det ails .
In Table 4.1, for any t ask X, standard in th e class column means st and ard classes
at tac hed to th e t ask th at are XForm and XAction. Similarly every dat a bean" class
Y has a YD at a class which is responsible for connect ing to the dat abase and for all
queries to th e database tabl e encoding data of type Y. As ~ach dat a bean class has a
corresponding Data class, it is not shown in the tabl e.
4.4.1 Single-Session Activities
Single session act ivit ies includ e all act ivit ies tha t a physician does during one session
of syste m usage. Thi s includ es the function s Login /L ogout (Sect ion 4.4.1.1), Search
Pati ent (Sect ion 4.4.1.2), and P rescrib e Regimen (Sect ion 4.4.1.3).
3See Footn ot e 2
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Table 4.1: Single User Design Table
Task Task Sub-Task Associated Classes
Duration (Section #) (Diagram #)
Single Login/L ogout Login (4.1) Stand ard + Physician
Session (4.4.1.1) Logout (4.1) LogoutA ction
Search Patient By MCP (4.3) Standard + Pati ent
(4.4.1.2) By Demographi c Stand ard + Pati ent
(4.5)
Pr escribe Regimen Pr escribe Regimen Stand ard +
(4.4.1.3) (4.6) Pres cription +
Regimen
Shor t Add Pati ent Add Pati ent Standard + Pati ent
Term (4.4.2.1) (4.9)
Creat e Regimen Creat eRegimen Stand ard + Regimen
(4.4.2.2) (4.11)
Alt er Regimen Alt er Regimen Stand ard + Regimen
(4.4.2.3) (4.15)
Manage Regimen Manage Regimen Stand ard + Regimen
(4.4.2.4) (4.18)
Mid Add Drug Add Drug Stand ard + Drug
Term (4.4.3.1) (4.20)
Password Retri eval Password Ret rieval Stand ard + Physi cian
(4.4.3.2) (4.22)
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4.4.1.1 Login/Logout
In order to log in to th e syst em , th e user ente rs his/h er usern ame and password
on the login screen. Th e system valida tes the usern ame and password against th e
inform ation in the dat abase. In the case of a match, the syste m crea tes the session
variables on the server, and users can use the chemot herapy prescript ion syste m. If
the login inform ation ente red by a user is incorrect that user is sent back to th e login
screen and error messages are displayed . Wh en a user selects th e logout option all
session variables are removed from th e server and th e user is brou ght back to th e login
screen . A workflow diagram for this function is shown in Figure 4.1, and a screenshot
of th e impl emented login page is shown in Figure 4.2.
Th e following decisions were made durin g the design of th e different featur es
involved in th e Login/Logout function:
1. Length of username a n d p assword: Th e security of a password is usually
measured by its length , bu t research has shown that if very lengt hy passwords
are enforced to increase secur ity it makes it more difficul t for users to rememb er
them, which causes them to write th em somewhere or to forget their password
too regularly [1]. Hence, the password should be length y enough th at it cannot
be broken and simultaneously should be small enough th at th e user can easily
remember it . We have followed the best practic es propos ed by Gartner [1], and
we have requir ed that password s have the following prop erti es:
• Th ey must be at least 8 cha rac te rs long
• Th ey may conta in alpha-numeric charac te rs
• Th ey are case sensitive
68
Figure 4.1: Workflow Diagram: Login/Logout
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I
Logon
Please enter your usemame and password
password : I
Don't have a username ?
Figure 4.2: Screenshot: Login
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• Th ey cannot be the same as the usern ame
Similarly, the usern ame is rest rict ed to a mini mum length of 6 cha racte rs.
2. Inva lid login attempts: Th ere is no limi t on the numb er of login attempts
by the user . Thi s may seem non-st and ard from the viewpoint of security, as
a common practice is to lock the user account after a fixed numb er of invalid
login at tempts. However , given th e clinical environment, where physicians need
to have constant access to th e system locking a physician 's account und er such
circumstances is not feasibl e.
4.4.1. 2 Search P a t ie nt
To find a pati ent from the database, the user ente rs the IvICP 4 numb er of th e patient .
In certa in cases, where a patent does not have an MCP numb er availabl e, the user
can use pati ent demographi c inform ation to search the patient . Th e chemot herapy
syste m searches the patient inform ation dat abase and returns results based on the
ty pe of search it performs. Workflow diagr ams for searching by MCP and searching
by demogr aphi c inform ation are shown in Figur es 4.3 and 4.5 respectively , and a
screenshot of th e impl ement ed pati ent search page is shown in Figur e 4.4.
Th e following decisions were made during the design of different featur es involved
in th e Pat ient Search functions :
4In order to uniqu ely identify pati ent s in th e pati ent dat ab ase, th ere is a need for a uniqu e key.
As the syste m is being impl emented in Newfoundl and and Labr ador , we are usin g th e Mer numb er
that t he provin cia l govern ment issues uniqu ely to every pati ent [52]. Note th at any impl ementat ion
of this system relati ve to anot her heal th car e juris dict ion would have to find a corresponding uni quely
identifyi ng num ber for pa t ients
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1. Search by MCP number: As the MCP numb er is unique for every patie nt ,
the primary search is based on MCP number.
Figure 4.3: Workflow Diagram : Patient Search by MCP Number
2. Search for patient 's demographic information: In search by demographi c
informat ion, users can enter the avai lable inform ation on a pati ent to search for
a pati ent or list of patients from the database . Thi s too l is ext remely helpful in
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emergencies or ot her cases where the pati ents MCP number is not available.
~~
HealthCare
Corpora tion of 51.John's
Patient Search
SearthbyMCP
Enter Mep Number;
Search byPatient PmonalInfonnation
Fir~tN:ll1le:
Last Name:
Gender: Iselect ::oJ
Dateof'Birth : ~rc;;y::Jrv;;-
Postal Code :
Figure 4.4: Screens hot: Patient Search Page
4.4.1.3 Prescribe Regimen
In order to prescrib e a regimen, the user must first searc h for the patient and then
look at the patient history (see Sect ion 4.4.1.2 for details of pati ent searc h). To
prescr ibe a regimen, the user selects a regimen from his private list of regimens (see
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Figure 4.5: Workflow Diagram: Patient Search by Demographic Information
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Sect ion 4.4.2.4) . T he system then generates the prescription with pat ient inform ation
on it, the user enters the pat ient height and weight, and the system calculates dosages
of different drugs (see below for det ails) . Th e user can make changes in dosages if
necessary. Once the system generates a printable vers ion of the prescript ion, the
user prin ts/ saves the prescription. T he workflow diagram for this process is shown in
Figure 4.6, and screenshot of the implemented presc ription input and out put pages
are shown in Figure 4.7, and 4.8, respectively.
Th e system calculates dosages of different drugs in a given regimen based on the
Body Surface Area (BSA) of the patie nt . T his BSA is calculate d using the height
and weight of the pat ient entered by t he physicia n, using following formula:
B S A (m 2) = Weight(kg)0.427 x H eight (cm )o.718 x 0.007449
Drug dosage is then typ ically a funct ion of BSA. For exam ple, the dosage for Cy-
clophospham ide is calculated as:
Cyclophosp hamide(mg) = 750mg x BSA
Note that, the user can modify auto mat ically calculate d dosages in two ways: Ei-
ther as a group, by applying a commo n factor to each, 0 individu ally by changing
indiv idua l dosage fields.
The following decisions were made dur ing the design of different featur es involved
in the Prescribe Regimen funct ion:
1. Sel ection of prescription: In orde r to show physicians the available regimens
to prescr ibe, the regime ns are div ided into two lists. Ph ysicians can find more
commo nly used regime ns in the primary list and less commonly used ones in
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Figure 4.6: Workflow Diagram: Prescribe Regimen
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~-~ PatientName:~
HealthCare Hasp. &.Ward: IHematologyCorporat ion of St. John's
MCPNumber I234-543.234
Medicine Program
Physician's Chemeth erapeutlc Medi cadon s ChartNumber123
Gene ralHosp italSite
Height=~ crns Weight=~kgs
Calculated BSA=2 .01m' BSAused=~ m'
TotalBih=r- ALP=~ CR=~
Diagnosis· lnil DrugAJIergies· lnil
Date: Pl /1212OO7 (MMIDDlYYYY)
Round off total dosages where appropriate
CHOP
Percent of Protocol Dose Intended by Physician: f1OO%3
Protocol Dose Calculated Dose Prescribed Dose
-
CYCLOPHOSPHAMIDE
750mg/m' 1510mg ~mg lV ove r 1 hour
DOXORUBICIN
50mg/m' 101 mg ~mg (i n a syri nge ) pushIV
VINCRISTINE
1.4mg/m' 2mg p- mg(MAXIMUM2 mg) in 20 mls Normal
Sahne (Ina syringe) push IV
PREDNISONE
100mg 100mg 100 mg POodfor5days
Thisprescription represents 100%oftheful1doseas per theprotocol
Drug Name Dose(mg) Route Frequency
ISlemetil (ProchlorperazineJ::J ["i"iG] ~ pre-cherno l
IAnzemet(DolasetronJ ::J f1OO3 ~ pre-chemo I
IOeCadrOn (OexamethasoneJ::J /83 ~ pre-cherno I
IAtivan (LorazepamJ::J ID'5::J ~ pre-cherno I
I Preview I
Figur e 4.7: Screenshot: Sampl e Pr escription Input Page
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p:::=~ PatientName: JohnHopkins
HealthCare Hosp.& Ward:HematologyCorporation of 51. [ohn'
MCPNumber:234 -543-234
Me dicine Pro gram
Physician's Chemotherapeutic Medications Chart Number: 23
General Hosp il al Site
Height =1 80cm s Weight = 80kgs
CalculatedBSA = 2.01or BSAused=20lm2
Total Bi1i= 4.0 ALP =5 .0 CR=2.5
Diagnosis-rulDrugAllergies-rul
Dale: 0811212007 04:04:26
Round off total dosages where appropriate
CHOP
Pe rcent of Protocol D ose Intended by Physic ian : 100%
Protocol Dose Calculated Dose Prescribed Dose
CYCLOPHOSPHAMIDE
750mglm2 1510mg 1500 mg IV over 1 hour
DOXORUBICIN
50mg/m2 101mg 100 mg (ina syringe) push IV
VINCRISTINE
1.4mglm2 2mg 2 mg (MAX IMUM 2 mg) in 20 mls Normal
Sal ine (in a syringe) push IV
PREDNISONE
100mg 100mg 100mgPOodfor5days
Thspre scriptionrepresenlsl00%ofthefulldoseasper e protocol
Drug Name Dcse Img) Rout e Frequency
Stemeti1(prochlorperazine) 10 po pre-cherno
Anzemet(Dolasetron) 100 po pre-cherno
Decadron(Dexamethasone) 8 po pre-cherno
Ativan(Lorazepam) 0.5 po pre-chemo
~~~
Figur e 4.8: Screenshot : Sampl e Pr escrip tion Ou tput Page
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th e second ary list. For det ails of the division of regimens into primary and
second ary lists see Section 4.4.2.4.
2. Automatic entry of data from previous prescriptions: To mak e th e
prescription writin g pro cess fast er , if th e regimen is already prescrib ed to th e
pati ent then dat a from th e last prescription is automat ically ente red to th e new
prescription by th e syst em . However , th e physician can make cha nges in th e
height and weight of th e pati ent if they have changed since th e last visit and
the syste m will calculate dosages based on the patient 's new bod y sur face area .
Moreover , th e physician can also make changes to th e dosages of different dru gs.
3. Automatic error checking: Major calculat ions involved in th e process of
pres cribin g are done by th e system to eliminate th e possibilities of manu al
calculation errors. Along with aut oma tically calculat ing dosages, th e syst em
also looks for any possibilit y of error while ente ring th e height or the weight
of pati ents ; if height or weight are beyond th e norm al rang e it will inform th e
orderin g physician about th e possibilit y of errors. Here, a norm al range for
height is 0-225 ern, and for weight is 0-225 pound s. Th e physician is notified
for any possibili ty of error by th e field color turn ing to red. Not e th at thi s is
consistent with th e error handling philosophy adopte d in thi s syst em, in which
pot enti al errors are flagged but allowed if th e physician considers it necessar y.
4. Future prescriptions: A physician can prescrib e a regimen with some futur e
dat e on it. Th e syste m allows prescribing a regimen in th e futur e becau se some
regimens have multiple courses of trea tment . However , to elimina te th e cha nces
of mul tipl e futur e prescriptions, th e syste m does not allow more th an one futur e
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prescription per pati ent . If a futur e prescription is already in datab ase for a
parti cular pati ent th en th e syste m will allow physicians to prescrib e only if t he
previous prescription is cancelled for that patient . Th e syste m will notify th e
physician of th e exist ing futur e prescrip tion and, if the physician elects to cancel
th e prescription, th e prescription is cancelled automa tica lly by th e syste m.
4.4.2 Short-Term Activities
Short te rm act ivit ies includ e act ivit ies that range from those th at run for one day
e.g., addin g a new pati ent to the system, to those which run for a year or more,
durin g which tim e new regimens are crea te d or physicians feel it necessary to make
changes in exist ing regimens. Short -t erm act ivit ies includ e adding new pati ents (Sec-
t ion 4.4.2 .1) , creat ing new regimens (Sect ion 4.4.2.2 ), and alt ering exist ing regimens
(Sect ion 4.4.2.3 ).
4.4.2.1 Add Patient
A user ente rs pati ent 's personal inform ati on to add him int o the syste m. If a pati ent
is already in th e dat abase the user is brou ght back to th ,add pati ent page with an
erro r message. A workflow diagram for this function is shown in Figure 4.9, and a
screenshot of t he impl ement ed pati ent regist eration page is shown in Figur e 4.10.
Th e following decisions were made durin g the design of different featur es involved
in the Add Pat ient function:
1. Selection of patient's unique identifier: To uniqu ely identify a pati ent in
a pati ent dat ab ase there is a need for a uniqu e key which will help to search
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Figure 4.9: Workflow Diagram: Add Patient to Database
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~~
HealthCare
Corporation of St. John's
Quick Links
Patient Registration
MCP Number : 1234543234
First Name : pOhn
LastName: IHopkins
Gender:~
Date of Birth :~ fi33 rrna
Steet Address :
j-----
City : 1St John's
Province : INewfoundland :.:I
PostalCode :~ (PCTmat:AHAIlAH)
Figure 4.10: Screenshot: Add Patient to Database
82
pati ent s in th at dat abase. For this purp ose, the pat ient's MCP numb er is used
(see Footn ote 4) .
2. Use of demographic information to identify patient: Different medi-
cal syste ms use different ty pes of keys to identi fy a pati ent in their patient
dat abases. Pati ent MCP numb ers and demographi c information are curr entl y
impl ement ed as keys in our syste m. Th e question naturally arises as to how
much demographi c information we are going to store . Stor ing more inform ation
might be bett er for futur es uses, such as linkin g wit h ot her datasets or commu-
nicatin g with oth er syste ms. However , in th e int erest s of pati ent priva cy and
sav ing memory space, we have elected to store what we consider the minimum
inform ation necessary for identification by demographi c inform ation .
4.4.2.2 Create New Regimen
In order to create a new regimen , the user suggests a uniqu e name for the regimen,
th e numb er of chemotherapy dru gs, and defines the scope of regimen , i.e., publi c or
privat e (see below). Th e user th en ente rs the det ails of chemothera py dru gs and th e
syste m validates chemot hera py dru gs against the dru g datab ase. If th e chemot hera py
dru gs are not in the datab ase th e syste m promp ts the user to add th e new dru gs and
their emetoge nicity levels (see Section 4.4.3.1 for det ails). If all ente red dru gs are
in the database, or have been added to the database, then the system suggests the
possible list of antiemetic drugs based on the emetoge nic levels of all chemot hera py
dru gs (see below). Here users can make changes to the list of ant iemet ic dru gs by
adding or deletin g dru gs/d oses from a group or changing th e order of dru gs/doses.
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Th e user then requests the final regimen and the syste m deve lops a regimen based
on th e inform ation entere d by the user and allows the user to save th e regimen to
the da tabas e according to the scope mentioned by the user. A workflow diagr am for
this function is shown in Figure 4.11. Screenshots of th e impl ement ed initi al pages
to initialize th e regimen , collect the det ails of chemot hera py drugs and to select
ant iemet ic drugs are shown in Figures 4.12, 4.13, and 4.14 respectiv ely.
Th e following decisions were made during th e design of different features involved
in th e Create New Regimen function:
1. Public and private regimens: Whil e creat ing a new regimen the physi cian is
asked to set th e scope of that regimen. Th e physician can mak e the new regimen
available just to himself, i.e., a privat e regimen , or he can make it publi c so
th at every physician in th e system will be notified about th e new regimen and
allowed to imp ort it to their private list. For det ails of th e Import Regim en
function , see Secti on 4.5.2.1.
2. Automatic selection of antiemetic: A decision support featur e is incorpo-
rat ed into th e syst em which helps physicians durin g th e select ion of anti emeti c
drugs . To make the syst em automatically select anti emetic drugs based on
th e emetogenicity pot enti al of chemotherapy drugs , an algorithm for predictin g
th e acut e emetogenicity of chemotherapy regimens was used. Recall that emeto-
genicity pot enti al of chemotherapy drugs is between 0-5 , with 0 havin g no effect
and 5 havin g max imum effect. This algorithm, developed by th e VHA Ph ar-
macy Benefits Management Str at egic Health care Group and Medical Advisory
Panel [79], is as follows:
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Figure 4.11: Workflow Diagram : Crea te New Regimen
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Health Care
Corporation of 51.John's
Quick Links
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(a) Identify t he most emetogenic chemot herapy drug in the regimen.
(b) Assess the relati ve contr ibut ion of ot her chemot hera py drugs to the emeto-
genicity of the regimen. Wh en consider ing ot her drugs the following rules
apply:
• Levell dru gs do not cont rib ute to the emetogenicity of a given regimen
• Add ing one or more level-2 dru gs increases the emetoge nicity of t he
regimen one level above the most emetogenic agent in the regimen
• Adding level-3 or level-4 dr ugs increases the emet ogenicity of the reg-
imen by one level per such drug.
Note that regardless of the fina l comp ute d value, if it is grea te r tha n 5 then it
is set to 5. In t his system, physicians can make changes in th e ant iemet ic dru gs
and their dosages as suggested by the algorit hm.
4.4.2.3 Alter Existing Regimen
In order to alter an existi ng regimen the physician selects an exist ing regimen from
his private list . Beca use t he new regimen could be conf sed with th e old one, the
physician is req uired to rename that regimen and select its new scope , i.e. , publi c
or private (see Sect ion 4.4.2.2). Th e system disp lays the list of all chemo-drugs in
the exist ing regimen. The physician ma kes changes in the chemot hera py dru gs, i.e.,
adding or delet ing chemot herapy drugs to the regimen , and can change the doses,
routes , frequencies or instructions associated with dru gs (see Section 3.2.1). T he sys-
tem then recomme nds ant iemet ic drugs based on t he new chemo drugs by using the
algorit hm described in Section 4.4.2.2. After this, the physician makes changes or
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approves the suggested ant iemet ic drugs and the system disp lays the final regimen
based on changes made by the physician who then saves the regimen. Th e workflow
diagram for this function is shown in Figure 4.15. Screenshots of the implemented ini-
t ial pages to rename t he existi ng regimen , and to collect detai ls of new chemot hera py
dr ugs and/or to delete exist ing dru gs are shown in Figures 4.16 and 4.17 respectively.
Th e page to select antie met ic dru gs in case of alter ing an exist ing regimen is the same
as shown in Figur e 4.14 for creat ing a new regimen.
T he following decisions were made duri ng the design of different featur es involved
in the Alt er Existing Regimen funct ion:
1. Renaming modified regimen: To mod ify an existing regimen the syste m
creates a new copy of that regimen in the datab ase and the exist ing regimen
remains unchanged. Changes are not perm itted in an exist ing regimen for the
following reasons:
• An existi ng regimen might be in use by ot her physicians who are not willing
to make cha nges in that regimen .
• An exist ing regimen might already have been prescrib ed by th e physician.
In order to display an old prescr ipt ion , the system maps prescription dru g
data to the regimen temp late stored in the database . Thu s, alter ing that
regimen temp late can cause prob lems when the syste m attempts to display
old prescript ions.
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Figure 4.15: Workflow Diagram: Alter Regimen
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4.4.2.4 Manage Regimens
Ph ysicians can manage th eir pri vate regimens by moving t hem to prim ary or sec-
ondary list s (see below). To move a regimen from one list to anot her the physician
selects the regimen to be moved and the system adds that regimen to the second
list and deletes it from the first. A workflow diagram for this function is shown in
Figure 4.18, and a screenshot of the impl emented manage regimen page is shown in
Figure 4.19.
Th e following decisions were made durin g the design of different features involved
in th e Manag e Regim ens function:
1. Purpose of regimen management: In orde r to make it easier for physicians
to find th e most frequentl y used regimens out of th eir all private regimen list ,
th e list is divid ed into prim ary and secondary regimens lists . The purpose of
th e primary list is to hold all regimens that are used frequently in prescribing
and displ ay th em first for regimen select ion during prescribin g. Th e physician
can move a regimen from one list to anot her at any t ime .
4 .4 .3 Mid-Term Activities
Mid-t erm act ivit ies include activit ies that ran ge from one to five years , where new
dru gs are introduced and are used as replacement s for exist ing dru gs in regimens .
Mid- term act ivit ies involve th e addit ion of new chemo-drugs to th e database (Section
4.4.3 .1) and the retrieval of lost passwords (Sect ion 4.4.3.2) .
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Figur e 4.18: Workflow Diagram : Man age Regimens
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4.4.3.1 Add New Chemotherapy drug
Whil e crea ting a new regimen (see Section 4.4.2.2) or alteri ng an exist ing regimen
(see Secti on 4.4.2.3) , if the physician ente rs a dru g name which is not in the dru g
database he/she is prompt ed to ente r t he new dru g into the datab ase along with the
emetogenic pot enti al of th at dru g. Th e physician ente rs the dru g name and th e syste m
th en generates a form to ente r the emetogenicity pot enti al. Next, th e physici an ente rs
ranges of dosages for all emetogenic levels of th e drug (see Secti on 3.2.1), which are
th en valid at ed by the system and stored in th e dat abase. Th e workflow diagram for
thi s function is shown in Figure 4.20, and a Screenshot of a th e impl ement ed page to
add new chemothera py dru gs to the syste m is shown in Figur e 4.21.
Th e following decisions were made durin g the design of different features involved
in Add New Chemoth erapy drug function:
1. A utomatic error checking for possible mistakes by the user: Th e range
of possibl e dosages of a drug is broken down in such a way th at th ere are sub-
ranges, each with their own emetoge nicity level. Th e union of th ese sub-ranges
must cover th e ent ire range, and th e emetogenicity level must incr ease as th e
dosage goes up. Wh en adding a new drug , th e syst em automat ically checks
for th e any possible errors in dosage ranges and emetogenic levels. Th ere are
four possible typ es of errors: Th e emetogenicity level can be out of range or
non-d ecreasin g and ranges can overlap or have gaps between them . For thi s
purpose, the physician has to ente r th e correct details of one eme togenic level
for a parti cular dru g, which is then examined by the syste m before th e physician
is allowed to proceed to the next level.
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Drug verified ?
Figure 4.20: Workflow Diagram : Add New Chemotherapy Drug
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Figure 4.21: Screenshot : Add New Chemotherapy Drug
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2. Direct addition of drugs to chemotherapy drug database without pass-
ing through administration: Ph ysicians are allowed to ente r new dru gs
directly into the dru g database wit hout any ap proval from the syste m admin-
istr ator. Th e add itio n of anot her ste p, i.e., approva l from the administrator,
could cause unn ecessary delays in the creat ion of a new regimen or alte rat ion
of an exist ing regimen, which is not tolerable due to the tim e-sensitiv e natur e
of the work physicians perform .
3. Automatic setting of missing limits for Emetogenicity levels of chemo
drugs: Any dru g with no specified upp er limi t for the highest emetogenic level
ente red has no upp er limit of dosages for th at parti cular level. This means th at ,
any dose ente red above th e lower limit of th at level is assigned th e emetogenicity
pot enti al of th at level. Moreover , the ra nge sta rt ing from 0 up to th e minimum
range specified for the lowest level ente red by the physician is auto mat ically
assigned an emetoge nic pote ntia l of 1. Tote that level 1 does not affect the
selecti on of ant iemet ic dru gs for a regimen (see Secti on 4.4.2.2 for details).
4.4.3.2 Password Retrieval
In order to retri eve his/h er password , a user needs to ente r his usern ame or email
address. Th e system validates the usern ame/ ernail of the user and mails the login
inform ation to the user email address store d in the datab ase. In the case of an invalid
usern ame/ email addr ess ente red by the user , that user is taken back to th e password
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retrieval page with an error message . The workflow diagram for this function is shown
in Figure 4.22, and a screenshot of the implemented password retrieval page is shown
in Figure 4.23.
Figure 4.22: Workflow Diagram: Password Retrieval
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Th e following decisions were made during th e design of different features involved
in the Password Retri eval function:
1. Information required to retrieve usernamejpassword: To mak e it sim-
pler for users to retri eve th eir passwords , th ey can eith er use their usernames or
th eir email addresses to retri eve th em; where th e system sends a password along
with th e username to th e email addr ess of th e user in question. This method is
also helpful in cases where users have forgott en th eir usernames allowing th em
to retri eve th em by ente ring th eir ema il addr ess into th e syst em .
2. Use of email address to retrieve usernamejpassword: We have looked
int o different commonly used ways to provid e a user his password [46]. Th e
basis for select ion of a method is th at it should be as simple as possibl e for th e
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user, and it shou ld be secure enough that no one can misuse it. One possible
way to give a password to a user is to send it to the email address which he/she
provides during the registration process. Another is by answering some secret
question which only the user can answer. This secret question is saved to t he
database, along with other information, during the registration process . Wh ile
making decisions about the method for password retrieval to be employed, it
was considered that it would an extra burden on the user to remember the
answer to the secret quest ion. Hence, the emai l address meth od is used here.
4.5 M ulti User Design
In the prev ious sect ion, we noted that single-user activities were div ided into session,
short-term, and mid -term activities. Multi-user activities can have duration from
single-session to mid-term. However , an important aspect of multi-user activities
is the type of interaction among users; hence , in the case of a multi-user design, we
have chosen to div ide act ivities into three categories based on the interacti on between
the users, namely indirect (Section 4.5.1) , limited direct (Section 4.5.2) , and direct
interaction (Section 4.5.3). These categories, along with their corresponding tasks ,
are shown in Tab le 4.2. Note that we are using the same task, subtask, and class
convent ions for Table 4.2 as were described in introduction Sectio n 4.4 for Tab le 4.1.
4.5.1 Indirect Interaction
Indirect interact ion between the users of a chemot herapy prescr ipt ion system happens
when a patient is treated by more than one phys ician . Here , physicians can not
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Table 4.2: Multi User Design Table
User Interaction Task Sub-Task Associated Classes
Type (Section #) (Diagram #)
Indir ect View pati ent View patient Stand ard +
history history Patient +
(4.5.1.1) (4.24) Pr escrip tion
Limited direct Import Regimen Import Regimen Stand ard +
(4.5.2.1) (4.26) Regimen
Driect Add Proposal Add Proposal Stand ard +
(4.5.3.1) (4.28) Admini str ator
Vote Proposal Vote Pr oposal Stand ard +
(4.5.3.2) (4.30) Adminis tr ator
View Pr oposals View Prop osals Standard +
(4.5.3.3) (Nj A) Admini str ator
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only view t he history of a patie nt and the way that patient is treated by the ot her
physicians, bu t also make changes in t he prescrip ti ons assigned by ot her physicians by
delet ing the exist ing prescrip tion . Th e only tas k that falls under indirect interaction
is viewing pati ent history (Sect ion 4.5.1.1).
4.5.1.1 View Patient History
After a successful search for a pati ent (see Sect ion 4.4. 1.2) the syste m displays the
patient 's history page. Here the physician can cancel, modify, or add comments to an
old prescript ion, or can prescrib e a regimen to the pat ient (see Section 4.4. 1.3). Note
that viewing patient history pa rt ially falls under the mult i-user environment, where a
physician can view the prescripti ons made by other physicians and can cancel them.
A workflow diagram for this functio n is shown in Figur e 4.24, and a screenshot of the
impl emented pati ent history page is shown in Figure 4.25.
Th e following decis ions were made duri ng the design of different featur es involved
in the View Patient History function:
1. Alteration of past prescription: Physicians can change any prescrip tion.
Such changes can only be made by the physician wh~ made th at prescrip tion.
2. Conditions under which a Physician can cancel a prescription: Any
physician can cancel any prescrip ti on prescribed by himself or any ot her physi-
cian within one day of the prescription being issued. Moreover , any futur e
prescription can be cancelled at any t ime by any physician. Note that it is
only in t he second scenar io where a futur e prescription can be cancelled. Under
Prescribe Regimen (see Sect ion 4.4.1.3) we see that if a physician prescrib es a
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Figure 4.24: Workflow Diagram: View Patient History
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regimen when an outstanding prescrip ti on is already in the syste m, the futur e
prescrip tion is automat ically cancelled by the syste m.
3. Addition of comments with each prescription ent ry : In order to enhance
communicat ion between the users of the chemot hera py prescrip tion syste m, any
physician can add comments on any prescrip ti on. Th is featur e can help the
physician in informin g ot her physicians about the reasons for his/h er act ions,
e.g., his/h er reasons for canceling a prescription.
4.5.2 Limited Direct Interaction
Limit ed dir ect int eracti on between the users of the chemothera py prescription syste m
occurs when a physician shows his interest in using a regimen crea ted by th e ot her
physician . Th e only tas k that falls und er limi ted dir ection int eraction is th e Imp ort
R egim en functi on (Sect ion 4.5.2.1).
4.5.2.1 Import Regimen
In order to imp ort a publi c regimen , the syste m displays the list of publi c regimens
available to the user . Th e user then selects the regimens he want s to imp ort and the
syste m adds them to the user 's private list . A workflow diagram for this function is
shown in Figur e 4.26, and a screenshot of the impl emented page to imp ort regimen
is shown in Figur e 4.27.
Th e following decisions were made durin g the design of different features involved
in Im port R egim en function:
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Figure 4.26: Workflow Diagram: Import Regimen
108
~ ~
HealthCare
Corporation of SI. John's
Quick Links
i> PresaibeReQimen
) Add catrent
• Create Regimen
) AJterReQiman
) Import Regimen (2 New)
• View Deleted ReOlmens
3>VlewReoimens
~ Admin
Regimen List
New Regimens
Comments
Modif ied version of Chop
Previously viewed regimens
Comments
Figure 4.27: Screenshot : Imp ort Regimen
109
1. Importing a regimen from a public list to a private list: In order to
increase collaboration and sharing among users , physic ians can make regimens
public while creating a new regimen (see Sect ion 4.4.2.2). T he pu blic list is
always available to all physic ians and displays all pub lic regimens that are not
already par t of a physician 's private lists. Each physician can, at any t ime,
imp ort a regimen from his/h er private list to the public list .
2. Alert physician of n ew regimen: To not ify physicians of a new regimen in
a pub lic list , each t ime a new regimen is added to the database, all physicians
in the dat abase are notified the next t ime they log in to the syste m by a display
of th e numb er of new regimens available to imp ort in front of the link to the
imp ort regimen page in the subtas k sidebar(see Figure 4.27).
3. Secondary list for viewed regimens: In order to different iate between the
viewed and unviewed public regimens , every publi c regimen that is not imp orted
by the physician , afte r looking at his prim ary list of publi c regimen , is sent to
a seconda ry publi c regimen list and can be imp orted at any lat er t ime.
4.5.3 Direct Interaction
Direct interaction is where the majority of syste m administration is done. System
administ rat ion und er the democrati c model is done by issuin g and vot ing on propos-
als (see Sect ion 4.2.1). T he ty pes of proposals cur rent ly impl ement ed are describ ed
in Sectio n 4.5.3.1. Th is process involves severa l funct ions. To make the vot ing mech-
anism simpler , we have intro duced a bull etin boa rd st ruct ure where physicians can
either make a new proposal (See Sect ion 4.5.3.1), vote on a prop osal (See Sect ion
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4.5.3 .2}, or view the status of an exist ing proposa l (See Section 4.5.3.3).
Th e democratic mode l of syste m operation has the following feat ures:
1. Bulletin board: In order to accommodate all types of system administration
featur es, a bulletin board st ruct ure was des igned. Thi s bullet in boa rd can
display all pendin g proposals which are not resolved (see Section 4.5.3.2 for
more details on prop osal resolution). Note that all prop osals tha t are resolved
are moved to a separate list . Here physicians can eit her add a new prop osal to
the bull etin board or can vote on an exist ing proposal.
2. Ability to issue proposals: Every physician who is registered in th e syste m
has the ability to make a proposal. Moreover, there is no maximum limi t on
the numb er of pro posa ls that can be made by a particular physician .
3. Resolution mechanism for proposals: All proposals are resolved in a demo-
crat ic fashi on, where physicia ns vote to eit her accept or reject the change re-
quested. However, the percentage of votes necessary for the acceptance of a
proposal depends on the crit icality of the change requested in that proposal
(see Sect ion 4.5.3.1). On ce a pro posa l is accepte d or rejected it is sent to the
resolved prop osals list , and any act ions requested by an accepted proposal are
automa t ically taken by syste m.
4.5.3.1 Add Proposal
In order to make a proposal , the user selects the new proposa l opt ion. Th e user
is asked to select a category of proposal and the system displays different proposal
types under the selected category. T he user then selects the proposa l ty pe and enters
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any requir ed data for that proposal. Th e syste m validates the data and saves the
proposal to the propos al database. A workflow diagram for this function is shown in
Figure 4.28 and a screenshot of the implemented page to add a proposa l to change
emetoge nicity potenti al is shown in Figure 4.29.
Th e following decisions were made durin g the design of different features involved
in the A dd Proposal function :
1. Types of Proposals: Th ere are many types of tas ks tha t can be perform ed
using the democratic model of syste m operat ion. However , in the system de-
veloped in this thesis, the availab le tas ks are as follows:
(a) Add user: Thi s prop osal is used to add a new user to the syst em . Any
exist ing user may make such a proposal , in which that exist ing user selects
a uniqu e usern ame and ente rs his/h er personal inform ation requir ed to
create an accounts . Th e crite ria for adding a new user is accepta nce by
two existi ng users. Upon successful accepta nce of the prop osal the new
user is auto mat ically added to the syste m.
(b) Delete user : Thi s proposal is used to delete ¥ exist ing user from the
syste m. Any existi ng user may make such a proposal , in which that user
ente rs th e usern ame of the user to be delet ed , as well as optional reasons
for deletion. Th e crite rion for deletin g a user is acceptance by 50 percent of
5T his is act ua lly an over simplificatio n. The current system does not allow usernames or pass-
words to be cha nged once ente red. Hence, we are assu ming th at t hough th e exist ing user tr iggers
t he func tion , the new user is act ually present and ente rs his usern am e and password in such a way
that the existing user does not see it , allowing it to remain private. We rea lize that this is awkward
and it should be fixed in t he futur e vers ions of t he syste m
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Figur e 4.28: Workflow Diagram: Add Proposal
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the exist ing users. Upon successful acceptance of the proposa l the selected
user is auto mat ically deleted from the system.
(c) Change chemot herapy drug name :Th is proposal is used to change the name
of chemot herapy dru gs in the dru g database. Thi s featur e is used to cor-
rect any misspelled dru g name in the dru g dat ab ase. Any exist ing user can
make such a proposal , in which the user enters bot h the exist ing and modi-
fied name of the dru g. Th e crite rion to cha nge the name of a chemothera py
drug is accepta nce by 60 percent of th e exist ing users. Upon successful ac-
ceptance of the proposal , th e dru g name is auto ma t ically changed in the
dru g dat ab ase. Note that this cha nge of chemothera py dru g name will
only affect fut ure regimens; for existi ng regimens, the name of the dru g
will remain the same.
(d) Change emetogenicity potentia l of chemot herapy drug: Thi s prop osal is
used to change the emetogenicity levels of chemot herapy dru gs. Th is fea-
ture is used to correct the range of any level or to add a new level to a drug.
Any exist ing user can make such a prop osal and ente rs the modified details
of the all emetoge nicity levels of the chemot hera py dru g. Th e crite rion to
cha nge emetoge nicity potenti al of a chemot hera py drug is accepta nce by
60 percent of th e existing users. Upon successful accepta nce of th e pro-
posal , th e old emetoge nicity levels of th e chemotherapy dru g are replaced
by the proposed levels. Note t hat emetoge nicity levels are used only while
creat ing a new regimen . Hence, a cha nge in emetoge nicity levels will not
affect the existing regimens.
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Note that each of the acceptance cr iter ia above also has an implicit rejection
crite rion. If X percent is the acceptance criter ion for a proposal then (100 - X)
percent is the reject ion criterion of that proposal.
4.5.3.2 Vote Proposal
In order to vote on a proposal, a user either accepts or rejects it . T he system saves
the vote in the proposal database, and when the acceptance or reject ion crite rion
associated with the proposal is met , that proposal is considered resolved . Th e system
performs the ad minist rat ive tas k if the proposal is accepted, and in eit her case, the
prop osal is sent to t he resolved proposal list. A workflow diag ram for this function
is shown in Figure 4.30; as voting on a proposa l is done on the same screen where
proposal status is viewed, see Section 4.5.3.3 for screenshot.
T he following decisions were made during the design of different features involved
in the Vote Proposal function:
1. User accepts a proposal when he/she adds it: A user who adds a proposa l
does not need to vote on it. New proposals added by the user are considered to
be accepted by the user who adds them.
2. Criteria for acceptance or rejection of proposal: A pro posa l is considered
resolved as soon as its acceptance or rejection criterion is met . Hence, not all
the users of system are requ ired to vote on a proposal when an acceptance or
rejection criterion is already fulfilled . Once a proposal has been resolved it is
moved to the resolved proposal list.
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Figur e 4.30: Workflow Diagram: Vote Proposal
117
4.5.3.3 View Status of Proposals
Wh en a user selects th e system administ ra t ion opt ion the syste m displays all the
outstanding proposals that remain unr esolved. A user can add a new proposa ls
(see Section 4.5.3.1) or vote on exist ing prop osals (see Secti on 4.5.3.2). A workflow
diagram of this function is shown in Figur e 4.31, and a screenshot of th e impl ement ed
page to view the status of proposa ls is shown in Figure 4.32.
Figure 4.31: Workflow Diagram: View P roposals
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4.6 Database Design
To implement the Entity objects that were described in Section 4.3 and used in pre-
vious sections, we have designed a database for our system consist ing of 18 schemas .
The relationships among these schemas , as well as their associated Entity objects,
is shown in Figure 4.33. As we can see from this figure, an Entity object may be
mapped onto a collection of several schemas .
The descr ipt ion of each schema is given below. Each schema consists of a collection
of attributes, where each attribute has an associated basic datatype. In each schema
the attribute that is the primary key is bold faced and a foreign key attribute is
italicized. An attribute is both a primary and a foreign key if it is bold faced and
italicized. A short description will be given at the end of each schema for any attribute
marked by a star (*) . Schemas are listed alphabetically by the objects they are
associated wit h as follows:
• Administrator
- Administrator (P roposa lID: integer, CreatorUsemarne: string, Status*:
enum, CreationDate: dat e/time, Comments: string, Category: string, Ac-
ceptanceCriteria: integer)
Status *: Status can be pending, rejected, or accepted .
- AddUserProposal (ProposalID: integer, Usemarn e: string)
- DeleteUserProposal (ProposalID: integer, Usemarne: string)
- ChangeEmetogenicityPotentialProposal (ProposalID: integer, DrugID : in-
teger , Level: integer, DoseUpperLimit: integer, DoseLowerLimit: integer)
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Figure 4.33: Database Entity-Relationship Diagram
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- ChangeCh emoDru gNameP rop osal (ProposalID: integer, DrugID : integer,
NewName: st ring)
• Antiemetic
- Regim enAnti Em eti cs(D atabaseGroupID :i nt eger, TradeName: st ring, Gener-
icNarne: st ring, Dose: float , Rout e: st ring)
• ChemoDrug
- ChemoDrug (D rugID : integer, Agent : st ring)
- EmetogenicityPotenti al (Drug ID: integer, Level: integer , DoseUpp erLimi t :
integer , DoseLowerLimi t : integer )
• Patient
- Pati ent (D atabasePat ientld: integer , FirstName: string, Last Name:
st ring, MCPN umber: st ring, Gender: str ing, Bir thd ay: dat e/ tim e, Str ee-
tAddress : str ing, City: str ing, Pr ovince: str ing, PostalC ode: st ring)
• Physician
- Ph ysician (U sername: str ing, Password: st ring, LicenseNumb er : st ring,
Fir stName: str ing, Last Name: st ring, DateAdded: dat e/ tim e, EmailAd-
dress: str ing, Act ive*: boolean)
Active *: Only physicians for which attri bute active is set to true can use
the system.
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• Prescription
- PrescriptionEvent (DatabasePrescriptionID: integer , DatabasePatientID:
int eger, Databas eRegim enID: integer, Cycl eNumber: integer , Prescription-
Date: date/time, Comments: string, PhysicianUsername: string, DoseRe-
duce: integer , Cancelled: boolean, CancelledBy: string, CancellationDate:
date/time)
- Prescription (DatabasePr'escriptionID: integer , DrugName: string, Calcu-
latedDose: float , PrescribedDose: float)
- BioPhysicalParameters (DatabasePrescriptionID: integer, Height: integer,
Weight : integer , CalculatedBSA*: float, UsedBSA: float)
CalculatedBSA *: BSA is Body Surfac e Area , calculated on basis of patient
height and weight (see Section 4.4.1.3 for details).
- PrescriptionAntiEmeticsDose (DatabasePrescriptionID: integer, DrugName:
string, DrugDose: float , DrugRoute: string, Frequency: string)
• Regimen
- Regimen (DatabaseRegimenId: integ er, RegimenName: string, Usernam e:
string, DateEntered: date/time, Comments: string)
- RegimenScope (DatabaseRegimenID: integer , PhysicianUsername:
string, CreaterLicenseNumber: string, Scope*: enum , View*: boolean,
CreationDate: date/time)
Scope*: scope can be public, private or default.
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View* : view is true if regimen has been viewed by physician, and false
otherwise.
- AntiEmeti csGroup (D atabaseGroupID : integer , DatabaseR egim enID : in-
tege r, GroupName: st ring)
- RegimenChemoDru gs (Database Regimenld: integer, Dru gID: integer , Quan -
tity : float , Measure: str ing, Max Dose: float , Instru ctions: st ring, Fre-
quency: str ing, Route: stri ng)
4.7 Summary: Implications for Medical Informat-
ics Development
We have learn ed the following lessons in the course of designin g our syste m:
• Wh en designin g medical syste ms, a key to success is to pay at tent ion to both
the workflow and the inter face of the new syste m. At tention to workflow for the
comp ute rization of hea lthcare is important because of its user guided acceptance
nat ure (see Section 6.1). Thi s will involve the physician champion who will
bot h ensure that the new system mimics the old system and guide workflow
and interface design decisions of t he new syste m. Moreover , where possib le,
deve lopers t hemselves should observe the existi ng workflow. In doing this on
our own system, we recogn ized that much of the syste m des ign consists of
guide lines rather than rigid requirements ; phys icians tend to brea k the rules in
the interest of patient care and any req uirement can rapidly become a guideline
which can be ignored at doctors' discreti on. Hence, a flexible workflow and
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interface is very important for a successful computerization of healthcare.
• Our second lesson is based on what we have noticed while computerizing a
small healthcare workflow, i.e., chemotherapy. Our experience on this project
suggests that focusing on a small healthcare workflow has benefits over working
on a larger and more general system:
- We can pay attention to and capture the details of the existing workflow in
a much better way that we can do it for a larger, more complex workflow.
- Though keeping it small results in the system operating under the Small
Organizational Model , which is a problem because of limited resources, by
adopting the democratic model , we can get around this resource problem
to a large degree.
- Last but not least, because we are dealing with a small and focused user
group with very well-defined needs and tasks, this approach allows us to
map system evolution much further forward into the future .
From the above , it is obvious that having one or more physician champions involved in
the design process is very important. Although it is desirable that wherever possible
computer literate physicians be involved in the design process, this level of computer
literacy should be fairly high. Physicians with little knowledge of computers can ac-
tually be dangerous to the design process, as they may insist on certain decisions that
they believe are correct based on their limited experience, and they may accidentally
limit the design process by omitting features that they believe (on the basis of their
limited experience) are too difficult to put into the system.
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We make following conject ures based on the lessons given above:
• Conjecture 1: Our "aim to small workflow" philosophy in conjunction with
the democratic model will work in ot her focused health care organizat ions.
• Conjecture 2: Our "aim to small workflow" philosophy leads to a "bot tom-up"
philo sophy for overall compute rizat ion of the health car e organi zation: Instead
of starting comp uter izat ion for all departm ents of a health car e organizat ion at
once , one should inst ead develop a collect ion of carefully selected focused groups
within that organizat ion that cover the range of possibili ties of vari ation in th e
whole syste m and from there develop the whole syste m.
• Conjecture 3: In this th esis, we viewed severa l mechanism s for involvin g physi-
cian champions in the syste m developm ent process. Our mechanism of choice
has been face-to-face meetin gs. However , more flexibl e schemes are possible.
For instance, one can have an on-lin e forum st ruc ture which can be used for
discussion on different screens or as an error repor tin g tool. We impl emented
such a st ruc ture at the early stage of the proj ect. Th ough we did not use it , we
conjec ture tha t in sit ua t ions where representative chdmpions must be involved
and their schedules do not allow frequent face-to-face meetin gs; such a system
may work well.
Conj ecture 1 brin gs up an interestin g point: does the democr ati c model works as well
for software syste ms in organizat ions ot her than health care, where instead of havin g
free agents like physician, we have more tradit ional-ty pe employees? Thi s will be
addr essed more in Chapt er 7.
126
Chapter 5
System Development
In this chapter we will describe the overall software architecture and technologies
underlying the implementation of our system as described in Chapter 4. We realize
that this design may be implemented differently relative to more advanced current
technologies or technologies that will evolve in future. However, we wish to describe
the choices we have made and the justification of these choices not only as documen-
tation of our system, but also as an example of how such technologies choices should
be made with respect to a medical informatics system. After a brief discussion of the
development process (Section 5.1), we will describe the MVC model (Section 5.2).
We will then move on to the various technologies used in this system (Section 5.3),
where we will describe both the available options and evaluate these options for their
suitability for medical informatics software. Finally, we will have a section on the
lessons learned during system development (Section 5.4).
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5.1 Development Process
As the Spiral model (Sect ion 2.3.2.4) was selecte d for th e deve lopment of the syste m,
the breakdown of system tasks in th e initial plannin g phase into single-user fea-
tures and multi-user features was helpful in dividin g th e syste m into sub tasks . First ,
single-user features were developed and afte r the successful developm ent of single-user
features, multi-user features were add ed to th e system. Each iteration includ ed th e
initial planning, requir ement gathering, design , developm ent , testin g, and evaluat ion
phases as shown in Figur e 5.1.
5.2 Development Model
In this section , we will discuss the overall syst em developm ent mod el. As this syst em
is web-bas ed , aft er a brief intr odu ction to web based technologi es, we will describ e
different models and evaluate them.
Consider the evolut ion of the web and its relationship to the software development
model [66]. In th e early days of th e web , web pages were only used as a sourc e of
information. Th ey were developed as static HTML pages, vhich were accessible over
th e int ern et . In th e past few years web developm ent tools and technologi es like J2EE,
which is used to execute Jav a applic ations on web servers, have enab led developers
to design multi-tier web applicat ions for large organiz ations. Web pages have now
become dynami c ent it ies th at allow the inpu t and displ ay of information and can
be crea ted or modifi ed dynami cally. Moreover , th ese web pages function as forms,
interacting with deeper logic in th e syst em .
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Initial Planning
Deployment
Figur e 5.1: Spir al Development Model
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As we see above, the evolut ion of web based systems has gone from static pages
to a fusion of display pages, which may be dynamic, and underlying code. Th is is
managed by the use of multi-tier mode ls. There are two such tier mode ls: the 2-
t ier mode l, and the 3-tier mode l. The 2-tier model naturally mode ls a distr ibuted
app licat ion. A distributed application is naturally split into two layers: the interact ion
layer and the processing layer. The interaction layer is used as the interface for the
user, where it displays data and receives commands from the user, translati ng data
or commands received from the user and delegating them to the process ing layer.
T he processi ng layer processes data and sends it back to the interaction layer. For
many app lications, a 2-tier mode l is sufficient, but if accessing data in the process ing
layer is comp lex then we should split the processing layer fur th er into two more
layers: the business logic layer and the data access layer, where the bus iness logic
layer encompasses all processing and the data access layer handles the tra nsfer of
data in and out of the database. T he resulting three-layer approach is used in the
Mode l-View-Controller (MVC) mode l of system deve lopment, where the developer
separates functions associated with data (Model) , user interface (View) and business
logic (Controller) into three different layers. As healt hcare organ izat ions often involve
comp lex data processing, we are using the MVC mode l as the deve lopment mode l of
our project .
5.3 Technology Decisions
Given our chosen development model , technological decis ions fall under four compo-
nents. We need a web development framework for building under MVC mode l, an
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IDE to manipulate things easily, a database, in order to store and access information
effectively, and a web server to run the application. In this section, we will list the
choices for each of these four components and then see which are most appropriate
for our project.
5.3.1 Development Framework
There have been many web development frameworks created under the scope of MVC
modeling. Every development framework has its primary advantages which force
developers to use the MVC model in web application development. Along with this
primary advantage, each framework has its own set of advantages and disadvantages.
In this section we will discuss the two major web deve lopment frameworks, Jakarta
St ruts and the Spr ing MVC Framework. Note that both of those frameworks are
based on J2EE technology. We will look at the advantages and disadvantages of
these frameworks, and we will discuss which framework is best for the deve lopment
of our chemotherapy prescription system.
5.3 .1.1 Jakarta Struts
Jakarta Struts [4] is an open source project by the Apache Software Foundation. It
is a Java implementat ion of the MVC model. T his project was originally created by
Craig McClanahan, but it was later taken over by the open source community. Struts
provides additional benefits , offering a collection of ut ilit ies to handle many of the
most common tasks of web application development .
Jakarta Struts offers the following advantages during application development
[66, 29, 28]:
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1. Centralized XML Configuration: Most configuration values are par t of
XML instead of being hard coded in Java files. Th is helps deve lopers to con-
cent rate on development tas ks rath er than caring for the system layout .
2. Struts Tags: Stru ts provides custo m tag libraries for HTML forms, which can
impl ement iteration on different ty pes of dat a st ruct ures , e.g., arrays of objects.
3. Form Validation: Struts offers an addit ional layer of form field valid ation ,
which is used to validate th e form dat a before any type of processing in th e
business logic layer. Thi s extra layer helps in breakin g down th e applicat ion
into differen t compo nents and also makes it faster , as valid ation is doric before
any ty pe of processing is done on form values .
4. Consistent Approach: Struts enforces a consistent MVC approach thro ugh-
out the web application.
5. Developer Support: Struts has a relati vely larger user community and a large
knowledge base, both on the web and in the form of books.
6. Testability: Testin g can be performed in St ruts using Stru tsTestC ase, an in-
buil t uni t test ing facili ty to test different objects in the syste m [64].
7. IDE Support: Stru ts has a lot of IDE support and even has IDE s built on
to p of it (see Section 5.3.2).
Th e major disadvantage of the Struts framework is that Struts is relatively hard to
understand for a new deve loper. It has a stee p learning curve, as the developer needs
to know bot h Java Server Pages (JS P) [72], a Java tec hnology to dynamic ally generate
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HT ML and XML, and Servlet [73], which can run Java code on the server and send
HTML pages to a browser , before learning th e st ru ts framework.
5.3.1.2 Spring MVC Framework
Th e Sprin g MVe framework [33] is also an open source framework for the Java plat-
form . It was first developed by Rod Johnson, and was first released und er an Apache
2.0 license in 2003. Th e Sprin g framework provides a fully funct ional MVe modul e
for web applicat ion developm ent . Th e Sprin g MVe fram ework provid es th e following
advant ages [33]:
1. Testability: Sprin g allows easy test ing with Sprin g Mocks, which is an inbuil t
unit testing facilit y used to test obj ect s in th e system
2. Highly configurable: Sprin g is designed in such a way th at every piece of logic
and functi onali ty is highly configura ble. Thi s makes it capable of int egrating
effort lessly with other popul ar frameworks.
3. JSP tag library (also known as the Spring tag library): Sprin g provides
a comprehensive set of ta gs for handling form elements when using JSP and
Sprin g Web NIVe . Each tag provides support for th e set of at t ributes of its
corresponding HTML tag counterpart, making th e t ags famili ar and intuitive
to use.
Th e maj or disad van tage of the Sprin g MVe framework is that as the Sprin g l'vIVe
fram ework is relativ ely new, it has a compara t ively smaller user community and fewer
resour ces, such as books and tuto rials.
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5.3.1.3 Evaluation of Struts and Spring frameworks
We have seen that bot h MVC frameworks have advantages and disadva ntages at -
tached to th eir usage. As th e Sprin g framework is relati vely new and has a sma ller
user community and less support for th e developers , th e Struts framework seems like
a ration al choice for an academic project. Moreover , for large applicat ions, Stru ts
enforces MVC , which is helpful in t he division of applicat ions into different layers
and best for an iterative developm ent approach such as th e Spiral model (see Section
2.3.2.4) , which was used for this proj ect. Hence, we will use Struts as a developm ent
framework for the developm ent of our chemot hera py prescription syste m.
5.3.2 Development IDE
A highly encouraging aspect of Stru ts is it 's massive support from different IDEs,
including Eclips e, Net Bea ns, IBM WebSph ere, Borland JBuilder X, Struts Console
and Struts Studio [76]. Out of th ese th e most popul ar are Eclip se! and NetB ean s.
Both NetB eans and Eclips e offer several wizards to aut omat e the proc ess of develop-
ment and simplify the complex st ruts environment. Netb eans has a gentl er learnin g
curve th an Eclip se. However , Eclip se is famous because of its light weight , i.e., min-
imal usage of memory and pro cessing tim e. Moreover , Eclips e has grea t support for
unit testin g, i.e., th e testin g of individual classes or collect ions of classes in isolation.
Given the benefits of Eclip se over Net Beans, Eclips e is the natur al choice for the
developm ent of our chemot herapy prescrip tion syste m.
1Eclip se alone does not suppor t Struts, but Eclip se with th e plu g-in MyE clipse mak es it th e most
popul ar ID E used for th e Struts developm ent fram ework. MyEcl ipse was develop ed in 2003 and has
cont inuously impro ved in each versio n [16].
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5.3.3 Database
Though there are many availab le database technologies , we have restricted our com-
parison to two of the most popular , MySQL [48] and Oracle [55]. MySQL is selected
for comparison because it is the best free, i.e., open source, database and Oracle
because it is the best commercially-available database.
The Oracle database is a full featured database engine that is well known for its
security and performance and is an obvious choice for any large application where
security and performance are primary concerns [57]. Moreover, due to it 's built-in
support for Java , developers can develop stored procedures, triggers, and functions
that can be executed in the database. On the other hand, MySQ L, a free ope n source
database, offers most of th e services that Oracle provides and also prov ides security
in terms of individual column locking . For any application, such as healthcare, that
has a strong need for security we recomme nded Oracle; however, as we are working
on an academic project, where cost is more important than security, a free database
like MySQL is more appropriate for our project.
5.3.4 WebServer
There are many available web-servers, but we have selected the two most commonly
used web servers that support J2EE for comparison, namely JBoss [62] and Apache
Tomcat [4]. The basic difference betw een these two servers is that JBoss is a complete
Java appl ication server; it supports EJB (Enterprise Java Bea ns) [71], is a compo-
nent architecture for the development and deployment of object-oriented, distributed ,
enterprise-level applications, and also includes the Tomcat server. On the other hand ,
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Apache Tomcat is used for the suppo rt of Java Servlet and Java Serve r Pages. Apache
Tomcat was chosen for our chemotherapy prescrip tion syste m due to its fast er load
tim e and lower memory usage. Oth erwise, both servers have similar featur es except
th at JB oss is capa ble of running EJB s, which we are not using in this proj ect .
5.4 Summary: Implications for Medical Informat-
ics Development
We have learn ed th e following lesson in th e course of developin g our syst em :
• Th e MVC model is the most widely used developm ent mod el in web appli ca-
tions . It is also th e most appropriate for medical informatics as well. Due to th e
cont inuously evolving health field , the MVC model mak es it easier for an en-
terpri se or software packager to cont inually evolve an applica t ion as new needs
and opportunities arise. Moreover , medical inform ati cs too ls and applicat ions
are usually compl ex syste ms. For such systems th e clear division of th e syst em
int o layers und er MVC model is very imp ortan t and I elpful to the developm ent
and main tenance of the syste m.
• Th ere are fact ors affecting technology choices in medicine. Given tha t we want
to ease accept an ce and have th e familiar look and feel of older syste ms, technolo-
gies should be chosen to be consiste nt with those used by th ese older syste ms.
Moreover , there are addit ional facto rs relate d to medical technology in general
and the small organizat ional setting. Security is paramount , regardl ess of what
level of organizati on you are workin g with and in th e small organizati onal set-
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t ing the technology must be able to function sem i autonomously and be cheap
because of limit ed resour ces.
Durin g the syste m development process, physician champions can st ill be a guide to
technology choices. Th e advice of physicians is useful to the exte nt that it helps you
find tho se factors in the workplace environment that dictate th ese choices. Th ese
factors may involve ty pes of technologies physicians are more famili ar wit h and are
more comforta ble using. However , we should pay at te nt ion to physician advice on
technology to the exte nt that the physician 's knowledge and experience does not
accide nta lly hamp er the deve lopment process (see Sect ion 4.7).
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Chapter 6
System Acceptance and
Implementation
In Chapters 4 and 5, we discussed the design of our chemotherapy prescription system
and the various technologies used during the development of the system. We observed
how the development of a software tool for a healthcare organization is different from
similar developments for other organizations and requires special considerations (see
Section 2.2.1.4) . Like other software development phases, the implementation of such
a system in a target workplace is also affected by these fac ors.
Though, as shown in Chapter 5, we have fully implemented and tested the system
described in Chapter 4, we have not been able to complete the user acceptance process,
i.e., the system has not yet been implemented in the clinical setting or tested by
clinicians not involved in the development process . However , this chapter contains
our notes on how this process should proceed. We will first discuss different models for
acceptance of new technologies relative to types of user communities (Section 6.1) , and
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we will see which mod el is applicable to th e accepta nce of medical inform ati cs syst ems.
We will th en discuss how a medical informatics syst em should be impl ement ed in any
health car e organi zation (Section 6.2) . Fin ally, we will discuss different lessons learn ed
for medical inform atics software in general (Section 6.3).
6.1 System Acceptance Model
In this section we will first discuss models for th e acceptance of new technologi es
relativ e to the different typ es of user communit ies, i.e., user-driven acceptance vs.
organization-driven accepta nce and th en discuss which model is most appropriate for
healthcar e organizations.
Th e most popul ar accepta nce model in existe nce is TAM , developed by Davis in
1989 [22], which was explicit ly phras ed in term of users in general. However , for
th e medical informatics environment we would like to distinguish between two forms
of TAM: the user-driven acceptance model, which corr esponds to the original TAM
model by Davis, and an organization-driven acceptance model [58] extended from the
original TAM mod el:
• User-Driven Acceptance: Thi s model describ es different factors th at are
involved in th e adoption of new software by individuals. Th e two main factor s
that are identifi ed in th e mod el are perceived usefulness and perceived ease of
use, Wh ere perceived usefu lness is defined by th e model as : "The degree
to which a person believes that using a part icular system would enhance his or
her job performance. "[22, pp . 320] and perceived ease of use is defined as:
"The degree to which a person believes that using a part icular sys tem would be
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fre e of efforts" [22, pp . 320]. In the real world, different constraints that are
applied to the TAM includ e t ime const raints, limi ted abi lit ies, organizat ional
limits, and unconscious habits, all of which affect the ind ividual accepta nce of
new technology [7].
• Organization-Driven Acceptance [58]: As noted abov e, different constraints
on TAM also inclu de organizational limits. The acceptance of a new software
or syste m by an orga nizatio n is mostly dependent on the man agement or IT
depar tm ent of the compa ny, who dictate to emp loyees the ado pt ion of that new
system. Indi vidual emp loyees consent is overridden by the decree of top man -
agement in the organ ization, who are responsible for allocat ing resources , or th e
IT division who are more familiar with the computer field and are considered in
a better posit ion to make a decisio n on the select ion of appro priate syste ms to
brin g about the desired changes . Hence, corporate culture has a maj or imp act
on the decision of individual users towar ds the adopt ion of new syste ms.
One could further sub-divide organization-dr iven acceptance, but th is is not relevant
for the purpose of our thesis .
Many st ud ies have extended, and used , TAM in different types of syst ems and
different fields which also include the examination of health eare professionals under
the TAM model [70, 18, 17]. Unlike ot her organ izations, where decisions are made
by management and the IT department and emp loyees follow what management
decid es, healthcare organizations are different due to the fact that decisions about
the select ion of any new techno logy are inde pendent of orga nizatio nal ma nagement or
IT divisions, preferring instead to use only those systems that are proven to be helpful
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for enhancing the process of patient care (see Section 2.2.1.4) . Hence , the selection of
a new too l/software for a physician falls under the individual user acceptance mode l,
such that the major factors that affect this decision are perceived usefu lness, perceived
ease of use , and the values of the medical profession.
6.2 Implementing Medical Informatics Software in
the Workplace
In the previous section, we noted that hea lthcare organ izations are differe nt from
many other organ izat ions, in that , acceptance of a new system by hea lt hca re organi-
zations is greatly dependent on the approval of the users of the system. In t his section
we will discuss how physic ians should be made part of the deve lopment process in the
hope that they will champion the resu lting system. The adoption process falls under
two parts: software adoption and imp lementation, which we will discuss in separate
subsections.
6.2.1 Software Adoption
As noted in Section 2.3.2, the initial stage of many software process mode ls is get-
ting requirements from potential users of the system under deve lopment. For this
purpose, users are involved to educate the technology experts about their require-
ments. However, in the case of a medical informatics software development, what is
really required is a partnership between the deve lopers and the users of the systems.
Here, users of systems may involve users other than physicians, e.g.) pharmacists. In
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that case, all ty pes of users must be consulted in every phase of syste m development .
To bett er und erstand the syste m IT experts need to exam ine the ta rget workpl ace
and watc h how people interact wit h each ot her in order to make the syste m flexible
enough that it fully follows the act ual healthc are workflow (see Section 3.1.4). More-
over, th ere is a need to involve all users of the syste m durin g the design decisions, so
th at th ey all feel invest ed in the final solut ion. In our case, the developm ent of the
chemot hera py prescrip ti on process, we involved physician champions not just in the
requi rement gat hering phase but in every developm ent phase of th e system, as seen
in previous chapte rs.
6.2.2 Software Impleme ntation
For the impl ementation of the system in the target workplace, there is to our knowl-
edge no model avai lab le in the software enginee ring literatur e. Under the Spir al model
(see Secti on 2.3.2.4) , which we are using for the deve lopment of our chemot hera py
presc ript ion syste m, end users sta rt evaluating different builds of the syste m from
the beginnin g of software deve lopment, bu t durin g the final impl ementation of the
syste m in the workpl ace we need to provide tra ining to all "users, especially to users
who were not involved in the syste m evaluat ion pro cess. After thi s training, there
are two ways to proceed : (1) have a system live dat e when users stop using th e old
syste m and shift to the new system, or (2) have the syste m impl ement ed in a tr ial
process". If the work place accepta nce is organizatio n-dr iven, setting up a specific im-
IT he second option is similar to beta testing [34], in that the new system operates in parallel
with the old system . However, in the case of beta testing the purpose is to establish correctness of
the new system, whereas here the purpose is to promote user acceptance.
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plementation date is possible and is the easiest way to implement a system; however,
if the workp lace has user-driven acceptance, as in healthcare organizations, systems
should be implemented in a number of trials before the actual implementation of the
system. Here, the purpose is to make sure that the new system adequately dea ls with
all possibi lities which are part of the healthcare workflow and ensure that the system
is error free before it is implemented. Otherwise, if users find errors, they will lose
confidence in, and stop using, the system.
6.3 Summary: Implications for Medical Informat-
ics Development
We have learned the following lesson in the course of preparing for the acceptance
and imp lementation of our system:
• As descr ibed in the lessons learned in Chapters 4 and 5, we chose represen-
tative physic ians champions based on their knowledge. In the acceptance and
imp lementation phase, we need to involve every user of the system. Given that
healt hcare has user guided acceptance, getting a system accepted by all users
will then help with any problems with the acceptance from IT department and
bureaucracy.
• After getting the whole user community involved, the next step is to make sure
not to lose them. Users can still reject the system if they lose their faith in
the system due to the wrong types of training or imp lementation methods. We
must make sure that software tools are error free before they are imp lemented.
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Moreover, before implementation, running a syste m in tri al mode parall el with
th e existing syst em (rather than running th e new syst em alone) can help in user
testing and can identify th e probl ems without losing th e faith of users on the
new system.
Th e role of physician champion at this point is now particularl y crit ical; moreover ,
it is mainly politi cal. If the repr esentative physician champions have been chosen
corr ectly, th ey are people who are deeply embedded in the user community and have
th e politi cal know-how and per sonal relationships th at will ensur e that th e new system
is accept able to th e whole user community. Not e how this situa tio n is different from
the typi cal impl ement ati on of software in busin ess organizat ions, where bureaucracy
and IT depar tm ents are in control and users have virtually no input or role in th e
accept anc e process.
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Chapter 7
Conclusion and Future Directions
In this thesis, we have developed an on-line web-based syste m for chemot hera py
prescrip tion. Thi s syste m ta kes into account a num ber of factors that are involved in
the developm ent of medical systems. In the course of developing this sys tem, we have
proposed the concept of syste m operationa l models. \Ve have noted that our syste m
falls und er the Small Organizational Model, and we have proposed a way of dealing
with the assoc iate d pro blems of limited resources for main tenance and evolut ion in
the design of such a syste m. We have also describ ed a num ber of lessons learn ed while
developin g thi s system which are applicable both to developin g similar syste ms and
to developin g medical software in genera l.
Th ere are numb er of dir ection s for futur e research. Th e most obvious of th ese
involve extensions to the syste m developed in this thesis:
• Different reportin g too ls can be added to the system, which will give people the
ability to ana lyze medical data. Thi s process of adding report ing too ls to the
syste m will need to go thro ugh anot her requirement gat her ing phase to collect
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inform ation about the ty pes of report that the end users want from the syste m.
• Th e syste m can be integrated to work wit h exist ing compute rized syste ms and
databases. It can be int egrat ed with exist ing patient or dru g dat abas es; it
could also be int egrat ed with any exist ing pharmacy syst ems to aid sending
prescrip tions in elect ronic form , providin g appropriate legislation is pu t in place
(see Section 2.2.1.3).
• Along with th e reports for prim ary care, administ rat ive and resear ch-ori ent ed
based reports can be generate d from t he pati ent and pres cription dat ab ases.
As such repor ts are no longer prim ary-care related and will not be read by th e
doctor s th emselves, we mus t impl ement dat aset anonymisa tion techniqu es to
ensure pati ent privacy (see Section 2.2.1.3).
More radi cal exte nsions of thi s syste m involve fund amental redesign . For exa mple,
as menti oned in Secti on 4.7, medical workflow consists of guidelines rath er than re-
quirement s. Hence, we can at tempt to build a much more free-form system, in which
not only the workflow which we have seen bu t th e full vari ability of that workflow is
impl emented in the syste m. Thi s might also includ e a more flexibl e user interface,
which physicians could custo mize according to th eir indi vidu al needs and preferences.
Th e work in this th esis also suggest s a possible line of softwar e engin eering re-
search. 'vVe have identified what we believe to be a gap in current practi ce related
to syste m operat ional models. In par ticular , we have identified a ty pe of syste m
(falling und er the Small Organi zati onal Model) which is not being handl ed well by
cur rent software developm ent practi ce. We have propo sed one way to getting around
problems assoc iated with this model, namely, the democrat ic model of system oper-
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at ion. However , as noted in Secti on 4.7, this model may not be applicable outs ide
of a user-ori ent ed environment like th at in health care. Hence we need to investigat e
alte rna t ives to the democratic model of syste m operat ion in health care syste m, eval-
uat e th e usefulness of th ese models outsid e health care, and furth er explore th e full
spect rum of syste m operationa l models that exist in software applicat ions in genera l.
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